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 ABSTRACT 
TITLE OF THE ABSTRACT  : CHARACTERISATION OF CELL      
POPULATION DATA AND ANGIOGENESIS   
IN MYELODYSPLASTIC SYNDROME.  
DEPARTMENT     : PATHOLOGY  
NAME OF THE CANDIDATE   : VISHNU CHANDRA KUMAR. A  
DEGREE AND SUBJECT    : MD. PATHOLOGY  
NAME OF THE GUIDE   : DR. JOY MAMMEN  
 
OBJECTIVES:  
1. To look for differences in the cell population  data (CPD) values and differences in the 
micro vessel density (MVD) in the bone marrow in cases of Myelodysplastic syndrome 
(MDS).  
 
METHODS:  
The Cell Population Data (CPD) values obtained from the automated cell counter (Beckman 
Coulter DxH800) of 68 cases with MDS were compared with 155 non MDS patients and 98 
normal healthy blood donors. The microvessel density in trephine biopsies of 101 MDS cases 
was counted using immunohistochemistry (antiCD34 antibody) by “hotspot” method and was 
compared with 35 normal controls.   
 
RESULTS:  
There was a significant increase in the mean neutrophil volume and mean monocyte volume 
in MDS cases compared to non MDS and healthy donors (p-value: 0.000 and 0.000 
respectively). A significant decrease in the neutrophil scatter and eosinophil scatter was noted 
in cases of MDS in comparison to non MDS and normal controls (p-value=0.000 and 0.000) 
respectively). A significant increase in the bone marrow mean MVD in cases of MDS was 
noted compared to the control marrows (p-value=0.000).  
 
CONCLUSION: There is a measurable  difference in the cell population data (CPD) in cases 
of MDS which can be detected at an early stage even before a bone marrow examination is 
carried out. The increased MVD in MDS is a potential target for antiangiogenic therapy.  
 
KEYWORDS: Myelodysplastic syndrome (MDS), Cell population data (CPD), Automated 
Beckman Coulter DxH800 haematology analyser,  Microvessel density (MVD). 
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INTRODUCTION: 
 
Myelodysplastic syndromes are a heterogenous group of hematopoietic disorders 
characterised by ineffective erythropoiesis in the bone marrow leading to decreased 
peripheral blood counts and their clinical consequences. They are premalignant disordersand 
can progress to acute leukaemia. These disorders are chronic in nature, resistant to treatment 
and cause considerable morbidity and mortality. The precise nature and pathophysiology of 
this group of disorders is currently under active research.  
The current diagnostic modalities for MDS include examination of peripheral blood film, 
bone marrow study and cytogenetic analysis. The morphological changes of the blood cells, 
especially in white blood cells can be picked up in the automated haematology analysers in 
addition to the labour intensive manual blood smear examination. The modern cell counters 
such as the Beckman Coulter DxH800 use the VCS technology (mean cell channel for 
Volume, Conductivity and Scatter) to provide a five part differential leucocyte count. The 
data acquired by the automated cell counter through the VCS technology is collectively 
known as the Research population data or the Cell Population Data. (CPD data). The present 
study aims to look fordifferences in the CPD in cases with MDS since this can spark an early 
clue to the presence of MDS even before a manual smear examination is carried out. 
The subsequent part of the study aims at assessing the degree of angiogenesis in the marrow 
of patients with MDS. Being a preleukemic condition, development of an increased degree of 
angiogenesis has been linked to a dangerous leap towards transformation to malignancy.  A 
precise understanding of the degree and patterns of angiogenesis can guide patient care and 
management with antiangiogenic therapies. 
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REVIEW OF LITERATURE: 
 
DEFINITION: 
 
Myelodysplastic syndromes (MDS) are clonal disorders of hematopoietic stem cells. They are 
characterized by ineffective haematopoiesis resulting in marrow failure, peripheral blood 
cytopenia(s) and dysplasia in one or more of the major myeloid cell lines. It is a preleukemic 
condition with a propensity to progress into acute myeloid leukaemia (AML). (1) 
HISTORY: 
 
MDS are a heterogeneous group of haematological disorders which have significant 
morbidity and mortality.  There are quantitative and qualitative alterations within one or more 
of the hematopoietic cell lines leading to progressive bone marrow failure.In 1923, an Italian 
physician named Giovanni Di Guglielmo described a set of bone marrow diseases which 
were associated with anaemia and bizarrely shaped red blood cells. This was called Di 
Guglielmo syndrome. It was noted that unlike pernicious anaemia the anaemia in this 
condition was resistant to liver therapy. Some cases that were once called  Di Guglielmo 
syndrome could now be called MDS.In the early 20
th
 century, it was recognised that a 
considerable number of persons with acute myeloid leukaemia had a preceding period of 
anaemia and abnormalities in the cell production.  These conditions were together recognised 
under the term “refractory anaemia”.  This term was used because attempts to treat the 
anaemia by replacement of the necessary nutrients did not succeed in cure and the patients 
remained unresponsive to all the active hematinics then known.  The term “preleukemia” was 
used by Block et al to include a set of patients with ill-defined and varied haematological 
conditions that terminated in the development of acute leukaemia. (2) 
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In the late 1950s,  William Dameshek proposed that even a small increase in the number of 
blasts in the bone marrow indicated the development of acute myeloid leukaemia(s). He 
coined the term smoldering leukaemia or low percentage leukaemia to identify this set of 
patients. He linked various forms of refractory anaemia to the development of acute 
leukaemia(s).(3) 
In the year 1976, theFAB classification published and popularised the term myelodysplastic 
syndrome (MDS). 
 
 
 
Figure 1:  Early history of Myelodysplastic Syndromes (MDS) 
 
 
 
 
Preleukemia 
Smoldering acute leukemia (1963) 
Idiopathic acquired sideroblastic anaemia (1956) 
Preleukemia anaemia (1949/1953) 
Refractory anaemia (1938) 
Di Guglielmo Syndrome (1920s) 
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ETIOLOGY:  
 
MDS can occur either as primary (de novo) disorders or secondary to previous treatment with 
chemotherapy, radiation therapy or immunosuppressive drugs in persons with organ 
transplantation or autoimmune disorders. Environmental and occupational factors like 
ionising radiation, smoking, pesticides and industrial solvents such as benzene are associated 
with an increased risk for primary myelodysplastic syndromes. Family history of 
haematological neoplasms and inherited hematologic disorders like dyskeratosis congenita, 
Fanconi anaemia, Diamond-Blackfan syndrome and Shwachmann-Diamond syndrome are 
also associated with an increased risk for primary MDS. (1) 
Therapy related MDS accounts for about 10% of all cases of MDS and has a poor prognosis 
compared to primary MDS.(4)  The common chemotherapeutic drugs that cause therapy 
related MDS are alkylating agents and topoisomerase II inhibitors.      
 
Figure 2: Etiological classification of MDS 
 
Myelodysplastic 
syndromes 
Primary(denovo) 
Secondary - 10% 
(Therapy related)  
Following cytotoxic drugs 
and radiation 
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EPIDEMIOLOGY: 
 
MDS is a disease of the elderly. Epidemiological data are available at present from large 
scale studies mainly from the western countries. Studies in the western population indicate 
that the peak incidence of myelodysplastic syndromes is seen in the sixth to seventh decade 
of life. (1)(5) Studies published regarding the prevalence and epidemiology of MDS  in India 
have pointed to differences in the epidemiology of MDS between Indians and the western 
population. The peak incidence of MDS appears to be a decade earlier in the Asian 
population, the exact reasons for which are not known. Factors such as environmental 
pollution, exposure to pesticides and toxic chemicals are believed to play a causative role. 
(6)(7) 
The non-age corrected annual incidence of MDS is 3-5/ 100000. But, the incidence rises to 
>20/100000 amongst those older than 70 years. Men are affected more than women. (1) 
 
CLINICAL FEATURES:  
 
MDS display clinical heterogeneity. Patients with MDS can be asymptomatic. The peripheral 
blood cytopenia(s) may be an incidental finding noted in a routine blood count. The clinical 
features range from an indolent disease with near-normal life expectancy to an aggressive 
behaviour overlapping with acute myeloid leukaemia. MDS isgenerally refractory to 
treatment and the majority of patients develop complications such as bone marrow 
dysfunction or hematopoietic neoplasm.(5) 
Anaemia is the most common cytopenia associated with MDS. It is found in approximately 
80% - 85% of patients.(8) Patients with anaemia manifest pallor, shortness of breath, fatigue, 
chest pain and palpitations exacerbated by exertion. Thrombocytopenia is seen in 35% - 45% 
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and manifests as easy bruising, mucocutaneous bleeding, purpura or petechiae. 
Gastrointestinal bleeding and intracranial haemorrhage may occur in severe cases.(8) 
Neutropenia manifests as recurrent bacterial infections. Organomegaly is uncommon in 
MDS. It can be present in cases with overlapping features of MDS and chronic 
myeloproliferative disorders.  
Clinical Scoring Systems: 
Scoring systems are used for MDS rather than staging systems. These scoring systems are 
based upon: 
 The number of myeloblasts in the bone marrow. 
 The number and degree of cytopenia(s). 
 Karyotypic abnormalities. 
Several investigators have attempted scoring systems using different parameters such as 
platelet count, haemoglobin, blast count and cytogenetic features.(9)(10) The most commonly 
used scoring systems are the International Prognostic Scoring System (IPSS) and the WHO 
Classification-based Prognostic Scoring System (WPSS). The latter system also takes into 
consideration the transfusion burden.(11) 
The International Prognostic Scoring System (IPSS)  was proposed by Greenberg and 
associates(12)in 1997. The IPSS includes blast percentage, karyotype of the bone marrow and 
the number of cytopenia(s) in the peripheral blood. The recommended thresholds for 
cytopenia(s) are haemoglobin <10g/dl, absolute neutrophil count <1.8x10^9/L and platelet 
count<100x10^9/L.  However, if the values are above these levels, MDS can still be 
considered if definite morphological or cytogenetic evidence is present.(1) 
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Few investigators also use the term “low grade” and “high grade” MDS. This division is 
based upon a bone marrow blast count of less than 5% and 5 or more than 5% respectively. 
This is not a routinely used grading scheme for MDS.(11) 
 
CLASSIFICATION OF MYELODYSPLASTIC SYNDROME: 
 
A succession of classification systems for MDS has been developed. The aim of these 
classification systems is to predict the overall survival and risk of progression to acute 
myeloid leukaemia.The classification of MDS was initially based on the French-American-
British (FAB) classification. The first FAB classification of MDS was proposed in the year 
1976 under the term “dysmyelopoietic syndromes”. This initial classification had only two 
categories namely, RAEB and Chronic myelomonocytic leukaemia (CMML). This was 
further revised in the year 1982.The revision included 5 categories which were RA, RARS, 
RAEB, RAEB-t and CMML (Table 2). The FAB classification was based entirely on findings 
recorded by cytological analysis of peripheral blood smear and bone marrow aspirate. The 
major criteria that were used for this classification of MDS were the percentage of blasts in 
the peripheral blood and bone marrow aspirates and the presence of dysplastic changes in the 
different bone marrow cell lines. (13) 
A more comprehensive approach for the classification of MDS was proposed by the World 
Health Organization (WHO) in the year 1999 to 2001, by incorporating changes in the 1982 
FAB classification. This early WHO (2001)classification system described MDS under 10 
categories. The alteration that was made include the following: RCMD, RCMD-RS, MDS-U, 
MDS with 5q (Del) and therapy related MDS were newly added. RAEB of FAB 
classification was split into RAEB-1 and RAEB-2. The category of RAEB-t was removed. 
CMML was moved to MDS/MPD category.  
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The WHO 2001 classification was further revised in the year 2008. This classification is 
currently in use. Presently there are 11 categories of MDS under this recent classification. 
Refractory neutropenia (RN), Refractory thrombocytopenia (RT) were considered along with 
refractory anaemia (RA) to comprise the category of RCUD. A new category of childhood 
MDS was added. RCMD and RCMD-RS were merged as one group.  
The WHO 2008 classification highlights the importance of integrating histologic examination 
of the bone marrow aspirate and the trephine biopsy with other diagnostic techniques such as 
cytogenetic analysis and molecular genetics, in the context of relevant clinical information.  
 
The WHO classification system recommends that at least 10% of the cells in a particular cell 
lineage should be morphologically dysplastic in the bone marrow to declare a dysplasia of 
that particular lineage.(1)(13)In particular, the extent of dysplasia, whether it is  unilineage or 
multilineage, has an important role in the WHO classification. This feature was not 
considered in the FAB system.(13) 
Recently, transfusion dependence has been identified to have an effect on survival of patients 
with MDS. As mentioned earlier, the consideration of transfusion dependency within the 
WHO system has produced the WHO classification–based prognostic scoring system.(13) 
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Figure 3: Evolution of classification of MDS 
Table 1: Myelodysplastic syndrome entities according to the WHO 2008 classification. 
Refractory cytopenia with unilineage dysplasia (RCUD) 
 Refractory neutropenia. 
 Refractory anaemia. 
 Refractory thrombocytopenia. 
Refractory anaemia with ring sideroblasts (RARS) 
Refractory cytopenia with multilineage dysplasia (RCMD) 
Refractory anaemia with excess blasts(RAEB) 
 RAEB-1 
 RAEB-2 
MDS with isolated del (5q) abnormality. 
MDS, unclassified. 
Therapy-related MDS (t-MDS) 
 
FAB 1976 (includes 2 categories )  
 " Dysmyelopoietic syndromes"   
    - RAEB and CMML 
FAB 1982 (includes 5 categories)  
" Myelodysplastic Syndromes" (MDS) 
   - RA, RARS, RAEB, RAEB-t, CMML. 
WHO 1999 (draft)/ 2001 (final) - (10 categories) 
 - RA, RARS, RCMD, RCMD-RS, MDS with 5q(del), MDSU,  
t-MDS due to alkylators, t-MDS due to topoisomerase 
inhibitors, RAEB-I and RAEB-II   
  
WHO 2008 (current classification) - (includes 11 
categories) 
 - Refer table 1 
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Table 2: Differences between the FAB 1982 classification and the WHO 2008 classification. 
FAB CLASSIFICATION(1982) 
(Old system) 
WHO SYSTEM(2008) 
(New system) 
Refractory anaemia (RA) Refractory cytopenia with unilineage 
dysplasia (RCUD) 
 Refractory neutropenia. 
 Refractory anaemia. 
 Refractory thrombocytopenia. 
 
Refractory anaemia with ringed sideroblasts 
(RARS) 
 Refractory anaemia with ring 
sideroblasts (RARS) 
 
 Refractory cytopenia with multilineage 
dysplasia (RCMD) including RCMD-RS. 
Refractory anaemia with excess 
blasts(RAEB) 
Refractory anaemia with excess blasts I 
(RAEB I) : 5-9% blasts. 
Refractory anaemia with excess blasts II 
(RAEB II): 10-19% blasts 
Refractory anaemia with excess blasts in 
transformation (RAEB-T) 
RAEB-T has been eliminated. It is now 
considered as acute leukaemia. 
Chronic myelomonocytic leukaemia 
(CMML) 
Removed from MDS. It is considered under 
the new category myelodysplastic-
myeloproliferative overlap syndromes. 
 5q- syndrome 
 MDS-U (myelodysplastic syndrome 
unclassifiable) 
 Refractory cytopenia of childhood (RCC) 
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APPROACH TO THE DIAGNOSIS OF MDS: 
 
The routine diagnostic workup of MDS includes a thorough clinical examination followed by 
the morphologic evaluation of peripheral blood smear, marrow aspirate and bone marrow 
trephine biopsy, which are interpreted in correlation with marrow cytogenetic results.(13) 
The correlation with marrow cytogenetics is also essential. The karyotype of the marrow is 
essential for the risk stratification and for the calculation of the IPSS score. However only 
50% cases of MDS show cytogenetic abnormalities. Hence, the presence of a normal 
karyotype does not exclude a diagnosis of MDS.  On the contrary, an abnormal karyotype 
may indicate MDS within an appropriate clinical context. (13) The role of cytogenetics in the 
diagnosis of MDS is discussed in the following sections. (page no: 29 – 31) 
 
PERIPHERAL SMEAR EXAMINATION: 
 
The peripheral blood smear in cases of MDS almost always shows some evidence of 
cytopenia. The red blood cells are macrocytic and the red cell distribution width(RDW) is 
often increased.(11) Dimorphic red blood cells with a combination of both macrocytes and 
hypochromic microcytes may be seen when there are significant ring sideroblasts in the 
marrow.(11)  A detailed cytomorphological analysis of 3156 MDS patients by Ulrich 
germing et al showed that, the most frequent features of dyserythropoiesis in the peripheral 
smear were anisocytosis, poikilocytosis and polychromasia. Patients with RARS subtype 
have more pronounced features of dyserythropoiesis in the peripheral blood.(14) 
Dysplastic features in the granulocytes are more easily appreciated in a peripheral smear than 
the marrow aspirate. The most frequent dysplastic sign in granulocytic lineage was found to 
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be  pseudo-Pelger cells followed by left shift in the white cell precursors and 
hypogranularity.(14) 
Anisometry of the platelets is also a frequent finding in all the subtypes of MDS.(14) 
Approximately  66 percent of patients have signs of dysplasia in the peripheral smear and 34 
percent patients do not show signs of dysplasia in a peripheral smear examination.(14) 
A clear relation between the presence of any particular dysplastic sign and the peripheral cell 
count has not been reliably demonstrated.  However, low cell counts can be associated with 
increasing number of signs of dysplasia in the marrow.(14) 
 
BONE MARROW ASPIRATE: 
 
This is a critical tool for diagnosis and subtyping of MDS. The percentage of blasts and 
degree of unilineage or multilineage dysplasia should be recorded. Dysplasia should be 
present in at least 10% of the cells of any lineage.(1)(11) 
The cytopenia(s) in the peripheral blood are thought to occur due to an enhanced degree of 
apoptosis in the bone marrow precursor cells. (1)The majority of patients have a norm 
cellular or a hypercellular marrow. 4-16% of patients also present with a hypocellular marrow 
many of  whom are in the RCUD category.(14) 
The features of dyserythropoiesis include nuclear budding, nuclear hyperlobation, 
multinuclearity, internuclear bridging, karyorrhexis, cytoplasmic vacuoles and cytoplasmic 
basophilic stippling. The presence of ring sideroblasts is another manifestation of 
dyserythropoiesis and is defined as at least five siderotic granules, covering at least one third 
of the circumference of the nucleus.(1) Ring sideroblasts are not specific for MDS. It can also 
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be seen in non-neoplastic conditions such as alcoholism, sideroblastic anaemia and due to 
certain drugs. 
 
Megaloblastoid change/ nuclear-cytoplasmic asynchrony is also considered as a feature of 
dyserythropoiesis. But this alteration can also be seen in non-MDS samples and hence needs 
to be interpreted with caution and should be correlated with other dysplastic features. 
 
Marked erythroid hyperplasia(50% or more) can be seen in about 15% of patients with MDS.  
These myelodysplastic syndromes with  erythroid predominance comprise a small, but a 
significant number of myelodysplastic syndromes.(15) Erythroid hyperplasia is more frequent 
in RARS and RCMD with ring sideroblasts. (14) On the contrary, 5% of MDS cases can also 
show marked erythroid hypoplasia or aplasia.(11)In the erythroid precursors, the nuclear 
changes of dysplasia are more frequent than the cytoplasmic changes.(14) 
The features of dysgranulopoiesis include nuclear hypolobation such as pseudo-Pelger-Huet 
anomaly (PPHA), hypersegmentation of the nuclei at inappropriate stage of maturation and 
alterations in the granularity of the cytoplasm (Hypergranularity, hypogranularity or 
agranularity). Identification of dysplasia in the myeloid cells can be challenging in cases of 
MDS when there is a left shifted myeloid maturation.(1)(11) 
Pseudo Pelger Huet anomaly is characterised by round or oval, peanut shaped nuclei or 
bilobed nuclei with abnormally clumped chromatin in the neutrophils. It resembles the true 
Pelger Huet anomaly which is an autosomal dominant disorder with normal neutrophil 
function.  PPHA anomaly is an acquired abnormality and is commonly seen in MDS and 
myeloid neoplasms. Traditionally, PPHA is associated with myelodysplasia.  It represents 
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severe degree of dysplasia in MDS cases and is associated with other abnormalities seen in 
MDS. (16) 
 
PPHA can also occur due to infections or due to medications such asMycophenolate mofetil, 
Tacrolimus, gancyclovir, fluconazole etc. used in conditions such as bone marrow 
transplantation or solid organ transplantations. .PPHA occurring in non-neoplastic conditions 
may be transient and is reversible. Factors such as spontaneous resolution of the anomaly, 
normalisation in the segmentation of the neutrophils and alterations in the proportion of 
neutrophils according to the dose adjustment of medication are helpful in attributing a non 
neoplastic cause to the PPHA. (16) 
An isolated PPHA without underlying MDS or other myeloid neoplasms usually have a 
higher proportions of PPHA cells (>30%) and are transient. In MDS, there are lesser number 
of PPHA cells in the peripheral circulation, but these are persistent and are not easily 
reversible.(16) 
Eosinophilia in the bone marrow has been identified in about 10% of the cases of MDS. MDS 
with eosinophilia is a rare entity and is yet not classified as a separate category in the current 
WHO 2008 classification. A study on 145 patients with denovo myelodysplastic syndromes 
by Matsushima et al documented certain features observed in the eosinophils  in MDS which 
were ring shaped nucleus,  disproportion in eosinophilic granule content, basophilic granules 
and vacuolation in the cytoplasm. In addition to these morphological abnormalities, 62% of 
patients who had eosinophilia in the setting of MDS have major karyotypic 
abnormalities.(17) 
Studies have shown a poor survival in MDS patients who have an increased proportion of 
bone marrow eosinophils and basophils. (18) On the contrary, few other case reports have 
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also recorded an indolent behaviour of MDS in the presence of persistent eosinophilia. (19) 
Hence the exact significance of eosinophilia and its clinical impact is unclear. 
The features of dysmegakaryopoiesis include micromegkaryocytes with hypolobated nuclei, 
pleomorphism in the size with monolobated nuclei. “Pawn ball megakaryocyte” is a form of 
dysmegakaryopoiesis that is used when the megakaryocyte has multiple widely separated 
nuclei. Dysplasia in the megakaryocytic lineage is better appreciated in the trephine biopsy 
sections. It helps to verify the findings seen on the BM aspirate smears.(11) An assessment 
should be made on atleast 20 to 30 megakaryocytes when possible and in both the biopsy 
sections and aspirate smears. Dysmegakaryopoiesis is extremely rare in the unilineage 
dysplasia types. The features of dysplasia in megakaryocytic lineage is more frequent in the 
more advanced types.(14) 
The study done by Germing U et alshowed that pseudo Pelger cells, hypo granulation, 
mononuclear megakaryocytes as well as micromegakaryocytes were the most important signs 
of non erythroid dysplasia and 85% percent of cases of RCMD could be diagnosed by the 
identification of these four parameters of dysplasia.(14) The presence of ring sideroblasts, 
platelet anisometry and a left shifted granulopoiesis are few uniform features of dysplasia that 
is seen in almost all cases of MDS.(14) 
MDS cases with unilineage dysplasia and absence of ring sideroblasts is difficult to diagnose 
on the basis of cytological assessment alone in the absence of clonal cytogenetic markers. In 
these instances, the limitations of cytology is obvious. 
 
BONE MARROW TREPHINE BIOPSY: 
 
In MDS, the bone marrow is usually hypercellular. The hypercellularity is thought to result 
from an increased production of the marrow cells to compensate for the peripheral 
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cytopenia(s). The topography of the marrow is considerably distorted. The stromal alterations 
include an altered cellular distribution of the constituent hematopoietic tissue with notable 
differences in the size of the hematopoietic islands, increase in the number of histiocytes,  
increasedmarrow vasculature, poorly formed erythroid islands, pleomorphism in adipocyte 
size and increase in the reticulin content. 
Though hypercellularity is the usual picture, a significant proportion (approximately 10%) of 
patients with MDS also have hypocellularity of the marrow.  These cases of hypoplastic 
MDS can be potentially confused with a hypoplastic marrow. (1) 
In many instances, it may be very challenging to distinguish hypocellular MDS from aplastic 
anaemia (AA). Macrocytosis of the red blood cells may be found in both the conditions. The 
presence of neutrophils with a pseudo-Pelger Huet anomaly  with or without a hypogranular 
cytoplasm favours a diagnosis of MDS over AA.(11)In a case of hypoplastic MDS, the bone 
marrow biopsies show scattered dysgranulopoiesis, lesser degrees of dysmegakaryopoiesis 
and patchy islands of dyserythropoiesis. There may be an uneven distribution in the 
cellularity wherein discernible dysplastic islands of hematopoietic cells are seen admixed 
with completely acellular areas.  
CD34+ve cells are decreased in marrows with AA. Though clonal cytogenetic abnormalities 
are identified in cases of MDS at the time of presentation, they can also be identified 
occasionally in cases of AA. 10-15% of cases with AA, who are not treated with 
hematopoietic stem cell transplantation develop MDS probably because of an independent 
clonal proliferation of cells with an acquired selective growth advantage(11) 
The expression of CD34, a marker of early progenitor cells, is increased in cases of MDS 
irrespective of the MDS subtype. Thus, immunohistochemistry can aid in the diagnosis of 
MDS, especially in cases with fibrotic or hypocellular bone marrow. It also assists in the 
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identification of Abnormal Localisation of Immature Precursors(ALIPs) which when present 
is correlated with an increased risk of transformation of MDS to acute leukaemia. (11) 
Dysplastic megakaryocytes in certain cases of MDS also show positive staining for CD34. In 
a study performed by Tang et al, they observed that in about 14% cases of MDS, there was 
expression of CD34 by megakaryocytes.  The expression of CD34 by the megakaryocytes in 
cases of MDS correlated with severe cytopenia, increased number of myeloblasts, presence of 
high risk cytogenetic abnormalities and reduced overall survival. This study concluded that 
expression of CD34 by megakaryocytes was a strong and an independent prognostic factor in 
cases of MDS.(20) 
Generally, the reason for the presence of cytopenia in the peripheral blood is believed to be 
due to increased apoptosis of the progenitor cells in the bone marrow. Electron microscopic 
studies in a case with trilineage dysplasia showed majority of the hematopoietic cells with 
ultrastructural features of apoptosis such as margination and condensation of nuclear 
chromatin, nuclear pyknosis, vacuolisation of cytoplasm and polarisation of the organelles. 
Hence the hypercellularity of the bone marrow appears to be a direct consequenceof an 
increased rate of apoptosis. 
Matsuda et al demonstrated that there was no correlation between the dysplastic lineage and 
the type of peripheral cytopenia in patients with unilineage dysplasias. (21)To elaborate 
further, there was no correlation between the peripheral blood absolute neutrophil counts and 
dysgranulopoeisis in the marrow. Hence, dysgranulopoeisis alone could not be considered as 
the only reason for a low absolute neutrophil count. So, dysplastic features in the granulocytic 
cells might be unrelated to ineffective erythropoiesis caused by increase in the rate and 
amount of apoptosis. (21) 
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Interestingly, in patients with dysmegakaryopoiesis, the peripheral platalet counts were 
higher than in those cases that did not have dysmegakaryopoiesis of 10% or more. This is 
similar to the pathology of 5q deletion syndrome, where the peripheral platelet counts are 
either normal or increased, inspite of the bone marrow harbouring megakaryocytes with 
>10% dysplasia.   
Moreover, 55% of patients with dysmegakaryopoiesis of 40% or more, had increased number 
of megakaryocytes. A similar correlation was present between the number of megakaryocytes 
and the presence of micromegakaryocytes. 75% of patients who had micromegakaryocytes in 
the marrow had an increased number of megakaryocytes. This study gives an indication that 
dysplasia may not completely correlate with an increased amount of apoptosis as believed 
widely.(21) 
 
IMPORTANCE OF ENUMERATION OF BLASTS IN MDS: 
 
An accurate assessment of the percentage of blasts in the bone marrow and peripheral smear 
is critical for the diagnosis, subtyping, risk stratification and assessment of treatment response 
in MDS. In certain studies, the percentage of blasts have been taken as one of the most 
important prognostic indicator.(13) 
Immature cells to be included while counting blasts include myeloblasts, monoblasts, and 
megakaryoblasts. The blast count derived from the aspirate should be correlated with the 
estimate from the biopsy sections.(13)For accurate blast enumeration, a 500 cell differential 
count is required.  
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A change in the number of  blasts can change the disease classification and predict clinical 
course and outcomes.(11) Circulating blasts and immature cells are also seen in those patients 
receiving growth factor therapy, in actively regenerating marrow, sepsis causing acute stress 
in the marrow and in those patients who have undergone a recent stem cell 
transplantation.(11) 
 
In trephine biopsies, blasts may be identified using  immunohistochemical stain for CD34. 
(13) However, it must be remembered that not all blasts are positive for CD34 and hence it 
should not be used as a substitute for careful morphological assessment.  Markers that can be 
used to visualise CD34 negative blasts are CD117, lysozyme and CD68.  Myeloperoxidase 
(MPO) is often weak or negative in the blasts seen in MDSs. Flow cytometry may help in 
assessing the frequency of marrow blasts and to confirm their immunophenotype. (13) 
The natural course of the disease, in many cases of MDS is progression to acute leukaemia. 
The proportion of cases with such transformation varies depending on the subtype of MDS.  
Persons with complex cytogenetic abnormalities or with subtypes such as RAEB-2 have a 
50% life time risk of transformation to acute leukaemia while “low grade” subtypes such as 
refractory cytopenia with unilineage dysplasia carry a life time risk of <5%.(22) 
Acute leukaemia arising from an underlying MDS is almost always of the myeloid lineage. 
Patients of MDS progressing to acute leukaemia develop complex cytogenetic abnormalities 
at the time of transformation. Those cases that have an initial response to treatment might 
acquire a second cytogenetic abnormality, become refractory to treatment and evolve into 
acute leukaemia. However, rare cases of MDS with transformation to ALL have also been 
documented in case reports.(23)(24) 
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According to the WHO system of classification (2008), the subtyping of MDSis not based 
only on morphologic findings. It also includes the use of clinical, genetic, 
immunophenotypic, and biologic information to define separate disease entities.Since,  a 
single biologic or genetic marker that identifies all or most cases of MDS has not been 
discovered till date, bone marrow morphologic assessment is important for subtyping the 
majority of cases of MDS. (13) 
 
REFRACTORY CYTOPENIA WITH UNILINEAGE DYSPLASIA: 
 
This category encompasses those MDS cases which present with a refractory cytopenia 
restricted to a single hematopoietic cell lineage and includes refractory anaemia (RA), 
refractory neutropenia (RN) and refractory thrombocytopenia (RT). (1) 
RCUD comprises of 10-20% of all the cases of MDS. Vast majority of RCUD cases are - 
refractory anaemia.  Refractory neutropenia and refractory thrombocytopenia are rare. 
(1)This designation encompasses the MDS cases that manifest with refractory cytopenia and 
associated with dysplasia limited to 1 cell line.  
Refractory bicytopenia can also be included in this category if accompanied by unilineage 
dysplasia.  The type of dysplasia in most of the cases corresponds to the type of cytopenia, 
e.g.  anaemia and erythroid dysplasia. The presence of blasts in the peripheral blood, 
generally excludes a diagnosis of RCUD..Refractory pancytopenia with unilineage dysplasia 
is best considered under MDS-U (MDS unclassifiable) because of the uncertain biology of 
the findings. 
Usually, the marrow is hypercellular and shows erythroid hyperplasia. Dyserythropoiesis is 
present, but ring sideroblasts are fewer than 15% of the erythroid cells.  In the absence of 
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cytogenetic abnormality, it requires cytopenia(s) for at least 6 months and the exclusion of  
reactive causes to make a diagnosis of RCUD.(13) 
Persons with RCUD have an indolent clinical course with a median survival of approximately 
66 months and a 2% rate of progression to AML at 5 years follow up.(1) It is generally 
considered a “low grade” MDS. In cases characterized by anaemia and dyserythropoiesis, 
conditions such as megaloblastic anaemia and congenital dyserythropoietic anaemia must be 
carefully excluded.  
 
REFRACTORY ANAEMIA WITH RING SIDEROBLASTS: (RARS) 
 
RARS is characterized by unexplained anaemia, and dysplasia involving the erythroid lineage 
with ring sideroblasts constituting >15% or more of the erythroid precursors. The dysplasia is 
confined to the erythroid cells. Anaemia is the predominant finding. The criteria are very 
similar to those described for RA, except that there are 15% or more of ring sideroblasts in 
the bone marrow. Ring sideroblasts can be seen in any of the subsets of MDS. AML and 
certain non-neoplastic conditions also show ring sideroblasts in the marrow. Hence, 
secondary causes of ring sideroblasts should be excluded before the diagnosis of RARS is 
made. Importantly, the myeloblasts should comprise <5% of the nucleated cells in the bone 
marrow and are usually not seen in the peripheral blood.(1) 
RARS is also considered a “low-grade” MDS. It is reported to have the best prognosis and 
lowest rate of conversion to AML among all the subtypes of MDS with a median survival of 
7 to 9 years or longer.  Approximately 1-2% of cases of RARS transforminto AML.(1)Ring 
sideroblasts are also seen in other subtypes of MDS such as RAEB and RCMD. Non 
neoplastic causes of ring sideroblasts include alcohol, toxins such a lead and benzene, drugs 
such as isoniazid, zinc supplementation and copper deficiency.(1)In rare occasions, the 
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platelet count is increased  (≥450 × 103/μL), and the differential diagnosis between a 
myeloproliferative disorder becomes problematic. (13)Most of these cases may be assigned to 
the provisional entity of RA with ring sideroblasts and thrombocytosis, which is currently 
considered within the MDS/MPN group.(13) 
 
REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA: 
 
This category was not recognized in the FAB system and has been added in the WHO 
classification.  This subtype accounts for ~30% cases of MDS. RCMD is characterized by 
one or more cytopenia(s) in the peripheral blood and dysplasia involving 2 or more of the 
myeloid lineages:  erythroid, granulocytic, and/or megakaryocytic lineages. There are less 
than 1% blasts in the blood and less than 5% in the bone marrow. Auer rods are not seen. If 
15% or more of the erythroid precursors are ring sideroblasts then the diagnosis of RCMD 
with ring sideroblasts should be made. (13) 
Cases that satisfy the criteria for RCMD but consistently have 1% blasts in the blood should 
be classified MDS unclassifiable, and those cases with multilineage dysplasia and lesser than 
5% blasts in the bone marrow but 2% to 4% blasts in the blood should be classified as 
RAEB-1. (13)The frequency of evolution into acute leukaemia at two years is ~10% for cases 
with RCMD. 
 
REFRACTORY ANEMIA WITH EXCESS BLASTS: 
 
RAEB is a myelodysplastic syndrome with 5% - 19% blasts in bone marrow or peripheral 
blood.  However, if there are lesser than 5% blasts in the bone marrow, the presence of 2% - 
4% blasts in the peripheral blood is adequate for the diagnosis of RAEB-1.  There are two 
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subcategories that are recognized based on the differences in survival and incidence of 
evolution into acute leukaemia: 
 
RAEB-1, defined as having 5% to 9% blasts in the bone marrow or 2% to 4% in the blood. 
RAEB-2, more than 10% blasts in the marrow and/or 5% or more in the peripheral blood.  
The presence of Auer rods shifts the classification to RAEB-2, regardless of the blast 
percentage.  
 
Patients with RAEB-2  have worse prognosis and a higher rate of transformation to AML.  
The median survival time is < 2 years in most studies, and although 30% to 40% of patients 
develop acute leukaemia, many die of the consequences of neutropenia, thrombocytopenia, or 
anaemia.(13) Median survival time for RAEB-1 is approximately 16 months vs 9 months for 
RAEB-2.(13) Approximately 25% patients diagnosed with RAEB-1 and 33% of patients with 
RAEB-2 progress to acute leukaemia.(1) 
In about 15% cases of MDS, there is significant reticulin fibrosis in the bone marrow. These 
cases have been called MDS with fibrosis(MDS-F).(1)The diagnosis of MDS-F requires the 
presence of diffuse, coarse reticulin fibrosis with or without concomitant collagenisation, 
associated with dysplasia in atleast two cell lines.(1) Most of these cases with fibrosis belong 
to the RAEB category because of the presence of excess blasts which can be demonstrated 
using immunohistochemistry for CD34.(1)  Marrow fibrosis can be present at the time of 
diagnosis or may develop during the course of the disease. Recently, the presence of marrow 
fibrosis has been recognised as an adverse prognostic factor in patients with primary 
myelodysplastic syndromes.(25) 
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MYELODYSPLASTIC SYNDROME WITH ISOLATED DEL (5q): 
 
Also termed 5q deletion syndrome. 
This subtype of MDS is characterized by anaemia with or without other cytopenia(s) and/or 
thrombocytosis and a sole cytogenetic abnormality of del (5q). Myeloblasts constitute less 
than 5% of nucleated bone marrow cells and less than 1% of peripheral blood leukocytes. 
Auer rods are not seen.  
This syndrome is more common in women with a median age of 67 years.  The proposed 
etiology is an interstitial deletion of the long arm of chromosome 5 which might have a 
possible tumour suppressor gene such as early growth response 1(EGR1) and a-
catenin(CTNNA1).(1)  Recently, a defect in ribosomal protein function due to 
haploinsufficiency of RPS14 has been identified in the pathogenesis of the 5q– 
syndrome.(13)Patients with isolated del(5q) have a very favourable response to the drug 
Lenalidomide.(13) 
 
MDS UNCLASSIFIABLE: 
 
This category encompasses cases that do not fit easily into the other categories of MDS. 
Three possible situations that fit for this diagnosis include: 
 Cases that have the criteria for a diagnosis RCUD or RCMD but with a percentage of 
1% blasts in the blood, detected consistently in at least 2 occasions. 
 MDS cases with morphologic unilineage dysplasia but associated with pancytopenia. 
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 Cases with persistent cytopenia(s) that lack the morphologic features of MDS (<10% 
dysplasia in any lineage) but with cytogenetic features with possible evidence of 
MDS. 
Patients with this subtype should be followed up carefully for evidence of evolution to a more 
specific subtype of MDS. 
The current revision of the WHO classification states “Cases with chromosomal 
abnormalities compatible with a myelodysplastic syndrome associated with strong clinical 
evidence of MDS but in which dysplastic features are  less than 10% of cells in one/ more of 
the cell lineages are classified as MDS, unclassifiable.(13) 
Occasionally, there are patients who have persistent cytopenia (usually anaemia) for which 
no underlying cause is found. They also have insufficient morphologic evidence to support 
the clinical possibility of an MDS. For some of these patients, a “working diagnosis” of 
idiopathic cytopenia of unknown significance may be considered. (1)(13) 
It is important to understand that this category is not synonymous with a diagnosis of MDS. 
 
CHILDHOOD MYELODYSPLASTIC SYNDROME: 
 
Myelodysplastic syndromes are very rare in children. Both primary and secondary MDS can 
occur. The “secondary MDS” may follow congenital or acquired bone marrow failure 
disorders and also following cytotoxic therapy. Certain significant differences are observed 
between MDS in adults and those in children. 
 Isolated anaemia, the common presentation in adults is uncommon in children. 
Neutropenia and thrombocytopenia are more common. 
 Hypocellularity of the marrow is more commonly seen. 
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Because of these differences a new term Refractory cytopenia of childhood has been 
introduced.(1) 
 
REFRACTORY CYTOPENIA OF CHILDHOOD (RCC): 
 
This is defined as a myelodysplastic syndrome characterised by persistent cytopenia with 
<5% blasts in the bone marrow and <2% blasts in the peripheral smear. 
RCC is the most common type of MDS in children constituting about 50% of the cases. It 
affects boys and girls equally. In addition to the dysplastic changes observed in bone marrow 
aspirate smears, examination of trephine biopsies is necessary for the diagnosis of RCC. The 
bone marrow cellularity may range from hypocellular to hypercellular, however majority of 
patients show a marked decrease in the marrow cellularity. Myeloblasts are typically less than 
5%. Ring sideroblasts are not seen. Megakaryocytes may be normal, increased or decreased 
in number.  
The detection of micromegakaryocytes is a strong indicator of RCC. The bone marrow 
reticulin content is normal. Most cases of RCC show a normal karyotype. Monosomy 7 is the 
most commonly observed karyotypic abnormality. Other complex karyotypes may also be 
found. 
 
It is noteworthy to remember that morphologic dysplasia is not necessarily synonymous with 
myelodysplastic syndromes (MDS). There are other non clonal causes of dysplasia which 
should be excluded in the appropriate clinical setting. These include a number of pathological 
conditions. 
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Dysplastic features may be observed in a briskly regenerating marrow. Conditions causing 
stress erythropoiesis such as haemolytic anaemias may show features of dyserythropoiesis. In 
patients with drug/toxin induced or autoimmune related neutropenia, the myeloid cells show 
left shift in maturation and may demonstrate hypogranulation or may contain abnormally 
coarse granules. In ITP, there are many young megakaryocytes that are often monolobated 
and hypergranular. 
Features of dysplasia are seen in inherited bone marrow failure syndromes. This may mimic 
MDS, especially in pediatric patients. Noonan syndrome, congenital dyserythropoietic 
anaemia, Pearson syndrome (mitochondrial disorders), Dobowitz syndrome, reticular 
dysgenesis, thrombocytopenia with absent radii (TAR) and amegakaryocytic 
thrombocytopenia can share some clinical and morphological features with MDS. These 
syndromes may not be necessarily associated with an increased risk of transformation to 
acute myeloid leukaemia. 
In persons with congenital bone marrow failure syndromes, hematopoiesis can show 
dysplastic features, particularly in the erythroid lineage. Many bone marrow failure 
syndromes cannot be separated from MDS based on the presence or absence of dysplasia 
alone. To make the distinction, a thorough clinical examination, physical examination, family 
history and other laboratory tests need to be considered.(11) 
In 29% to 45% cases of paediatric MDS, an associated constitutional abnormality is present. 
The development of MDS in such settings should be considered if hypercellularity of the 
bone marrow develops in the presence of peripheral cytopenia(s) or if a persistent clonal 
chromosomal abnormality is detected. 
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Table 3: Myelodysplastic syndromes – Differential Diagnosis 
MDS Distinguishing features 
Peripheral destruction (haemolytic anaemia, 
ITP) 
 Preserved bone marrow topography. 
 Hyperplasia of cytopenic lineage. 
 Increased or normal hematogones 
Growth factor treatment  Clinical history. 
 Minimal morphological dysplasia 
 Hypergranulation in neutrophils 
Aplastic anaemia  No increase in the CD34 + precursor 
cells by immunohistochemistry. 
 Mild dysplasia often in erythroid 
lineage. 
Bone marrow failure syndromes (congenital)  Clinical and family history. 
 No clonal cytogenetic abnormality 
Hairy cell leukaemia  CD20 +ve neoplastic B cells in the 
bone marrow biopsy. 
 
 
 
ROLE OF CYTOGENETICS IN THE DIAGNOSIS OF MDS: 
 
Cytogenetic profile has become a standard practice in the diagnosis of myelodysplastic 
syndromes. It is a major indicator for predicting clinical course and outcome.(7) 
Clonal cytogenetic abnormalities are noted in approximately 50% cases of primary or denovo 
MDS and upto 80% of myelodysplastic syndromes that develop secondary to chemotherapy 
or other toxic agents. (26) 
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Table 4:  Chromosomal abnormalities in myelodysplastic syndrome (MDS) 
UNBALANCED BALANCED 
+8 t(11;16)(q23;p13.3) 
del(7q) t(3;21)(q26.2;q22.1) 
del(5q) t(1;3)(p36.3;q21.2) 
del(20q) t(2;11)(p21;q23) 
-Y t(6;9)(p23;q34) 
t(17p) Inv(3)(q21;q26.2) 
del(13q)  
 
Conventional karyotyping is an essential component of the diagnostic work up of any patient 
suspected to have MDS. They form the basis for the selection of  drugs for individual cases of 
MDS.  Myelodysplastic syndromes show characteristic genetic profile, the majority of which 
are unbalanced translocations. Unlike in cases of acute myeloid leukaemia, cases of MDS 
show partial or total chromosomal losses, high incidence of chromosomal gains and rare 
translocations. But, the results have to be interpreted with caution. The presence of these 
cytogenetic abnormalities as the sole finding in the absence of the morphological features is 
not considered as a definite evidence for MDS. (1) 
 In order to avoid false positive results, a standard definition for clonality such as the 
presence of same chromosomal gain or structural aberration in at least two bone marrow cells 
and the same chromosomal loss in at least three bone marrow cells is essential. 
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In a study by Chaubey et al, on the cytogenetic profile of myelodysplastic syndrome in 50 
Indian patients, the most common cytogenetic abnormality was Monosomy 7. The other 
abnormalities were del (5q), +8, del (6q) and del (3q) in the decreasing order of frequency. 
Del (6q) and del (3q) were two new cytogenetic abnormalities that were not described so far. 
They found clonal cytogenetic abnormality in 47.5% of cases which is comparable to the 
published data so far.(7) 
The loss of 17p is associated with MDS or AML with pseudo-Pelger Huet anomaly, TP53 
mutations, small vacuolated neutrophils and an unfavourable clinical outcome.(1) Complex 
karyotypes which include >3 cytogenetic alterations typically include chromosome 5 and/or 7 
and are generally associated with an unfavourable clinical course.(1) 
Isolated del(20q) is associated with morphological abnormalities involving the erythroid and 
megakaryocytic lineages.(1)Inversion (3) is a rare cytogenetic abnormality in MDS. It is also 
noted in cases of AML and blast phase of chronic myeloid leukaemia. The bone marrow 
biopsies of cases of MDS with inv (3) are usually normocellular or hypercellular and show 
megakaryocytic hyperplasia.  The megakaryocytes have a monolobated or hypolobated 
nuclei. The blast count ranges from 0 to 10%.  MDS cases associated with inv (3) have a poor 
clinical outcome, resistant to chemotherapy and have a higher risk of transformation to acute 
myeloid leukaemia.(27) 
The IPSS uses cytogenetic abnormalities to stratify cases of MDS into three different risk 
categories, namely good, poor and intermediate.(11) 
Good: Includes normal karyotype, isolated interstitial del (5q), isolated del (20q) and –Y. 
Poor: Includes cases with complex karyotype, del (7q) and -7 
Intermediate: Includes all other abnormalities. 
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IPSS prognostic subgroup, proportion of the marrow blasts and haemoglobin level was found 
to be the main prognostic factors for survival. (28) The first two factors and the platelet count 
were the best predictors for risk of transformation to acute leukaemia.(28) 
 
ROLE OF FLOWCYTOMETRY: 
 
Immunophenotyping using flowcytometry is not routinely used in the diagnosis of MDS. But, 
flowcytometric immunophenotyping has been shown to correlate with cytogenetic 
abnormalities and morphological dysplasia. The objective of flowcytometry is to identify 
dysregulated antigen expression in the neoplastic cells. The advantage of flowcytometry is 
that, it is less subjective, more sensitive and less affected by the quality of specimen when 
compared to the morphological assessment of dysplasia.(29)(11) Flowcytometric 
abnormalities alone are not sufficient to arrive at a diagnosis of MDS .(1) 
The diagnosis of MDS by flowcytometry is based on the interpretation of altered patterns of 
maturation and myelomonocytic differentiation, by using combination of antigens such as 
CD11b/CD16, CD33/HLA-DR, CD13/CD16, CD64/CD10. There are certain limitations to 
this method. Certain conditions such as a regenerating marrow, growth factor therapy, severe 
infection, acute bone marrow insults, HIV and autoimmune disorders also might show 
alterations in the myelomonocytic maturation patterns by flowcytometry. Abnormal 
expression of some markers such as a decreased CD33 expression can be due to genetic 
polymorphisms and not necessarily due to dysplasia. 
 
The other approach in the diagnosis of MDS is by focusing on the phenotype of myeloblasts. 
In a reactive marrow, CD34+ve cells show diverse differentiation and maturation patterns. 
Normally, CD34+ve stem cells are capable of producing hematogones (CD19+ve and CD10+ 
33 
 
immature B-cells precursors), myeloid precursors (CD34+ve, CD65+ve, CD15+ve), 
monocytic precursors (CD34+ve, CD4+ve, CD64+ve) and plasmacytoid dendritic cell 
precursors (CD123+ve(bright), HLA-DR+ve). In MDS, the CD34+ve blasts are clonal 
forming a discrete population without evidence of differentiation towards monocytes, 
hematogones or plasmacytoid dendritic cells. Aberrant expression of lymphoid antigens such 
as CD2, CD7, CD5 and CD56 can also be noted.   
 
A positive flowcytometry result does not help to distinguish MDS from MDS/MPN or from 
MPN. Chronic idiopathic myelofibrosis can show similar changes like MDS.  The better 
approach for cases with borderline features of dysplasia and no cytogenetic abnormalities 
showing features of MDS in flowcytometry, would be to perform a re-evaluation after several 
months to look for morphological and cytogenetic features of MDS. 
Flowcytometry is not a recommended method for enumeration of the percentage of blasts.All 
the myeloblasts donot express CD34 and cells such as early hematogones can also express 
CD34.  Hence, flowcytometry underestimates the percentage of blasts.  Morphological 
counting or immunohistochemistry done on the trephine biopsy sections are more useful for 
the assessment of blast percentage.  
 
ROLE OF FLUORESCENCE IN SITU HYBRIDIZATION (FISH) IN MDS: 
 
In MDS, FISH has been used to identify recurring genetic abnormalities. The panel include 
probes for del (5q), del (7q), trisomy 8 and del (20q).FISH can be helpfulin cases of MDS 
with karyotype failure, in cases of RAEB and RCMD with a normal G-band karyotype. The 
usefulness is limited in cases of RCUD and in cases with an abnormal karyotype by 
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conventional karyotyping. The advantage of FISH is its high sensitivity due to the number of 
scorable cells compared with routine analysis of only 20 cells by cytogenetics.  
Comparative genomic hybridization arrays,  single-nucleotide Polymorphism arrays and 
molecular testing are other tools that have been found to be useful in the diagnosis of MDS, 
but are not used in routine practice.  
 
ANGIOGENESIS IN MYELODYSPLASTIC SYNDROME: 
 
Angiogenesis or neovascularisation is formation of new blood vessels from pre-existing 
vessels. The process of angiogenesis can occur by two mechanisms. The first mechanism is 
by branching and extensions from pre-existing vessels. The second mechanism is by the 
recruitment of endothelial progenitor cells to the site of formation of the new vessel. (30) 
Angiogenesis is a basic process that affects day to day physiological reactions such as wound 
healing, regeneration, menstruation etc. Angiogenesis also plays a prominent role in 
pathological processes such a development of tumours and metastasis, chronic inflammation 
and conditions such as diabetic retinopathy.  
The process of formation of new vessel from a pre-existing vessel involves vasodilation, 
proteolytic degradation of the basement membrane of the parent vessel, movement and 
proliferation  of the endothelial cells towards the angiogenic stimuli forming capillary 
sprouts, maturation of endothelial cells and stabilisation of the new vessel by recruitment of 
periendothelial cells.(30) 
Neovascularisation also occurs by the mobilisation and recruitment of endothelial progenitor 
cells from the bone marrow to the site of injury or tumour. These endothelial progenitor cells 
also express some markers of hematopoietic stem cells, VEGFR-2 and VE-Cadherin. 
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Angiogenesis is controlled by a balance between angiogenesis inhibitors(angiostatin, 
endostatin and vasculostatin) and promoters(VEGF and bFGF). The angiogenic switch is 
activated either by a loss of angiogenic inhibitors or increased production of angiogenic 
promoters. The angiogenic switch is also upregulated by hypoxia. The lack of oxygen in the 
cell environment stimulates production of HIF1a(Hypoxia induced factor 1a) which 
upregulates the promoters of angiogenesis such as VEGF thus creating a proangiogenic 
environment. (30) 
 
VASCULAR ANATOMY OF THE BONE MARROW: 
 
The bone marrow can be subdivided into a hematopoietic compartment and a stromal 
compartment which is constituted by fibroblasts, adipocytes, nerves and the vascular system. 
(31) 
The arterial vessels enter the marrow through the nutrient foramen and branches into several 
arterioles. Smaller arterioles and capillaries arise from these vessels, span the entire marrow 
space and feed the sinusoids. The sinusoids are interconnected by capillaries. These sinusoids 
are located around a central draining sinus which measures about 100microns in diameter. 
The bone marrow sinusoids are formed by a single layer of endothelial cells with no 
supporting structures. (32) The surrounding hematopoietic tissue appears to be the major 
cellular support for the sinusoidal microcirculation.(31) 
Angiogenesis has been shown to affect the pathogenesis and prognosis in patients with 
myelodysplatic syndrome. A study performed by Savic et al, by investigating 70 patients 
with MDS showed an increased microvessel density (MVD) in patients with MDS. However, 
they found that angiogenesis was not an independent prognostic factor in patients with MDS. 
(33) 
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By assessing the angiogenesis in 82 patients with MDS and comparing it with 14 controls, 
five cases with infectious disease, 15 cases with AML and 14 patients with MPD,  Pruneri et 
al, demonstrated that neovascularisation in cases of MDS was intermediate between those of 
controls and AML. They suggested that increased MVD could correlate with transformation 
of MDS into leukaemia. (34) 
In the above study, the investigators used anti CD34 antibody and anti CD31 antibody to 
evaluate the degree of angiogenesis/ neovascularisation. They have shown that anti CD34 
antibody is superior to anti CD31 antibody for assessing the MVD. The anti CD34 
immunostain highlights variable number of blasts and  endothelial cells in the bone marrow. 
There was good inter observer reproducibility when anti CD34 immunostainwas used to 
assess the degree of angiogenesis. The MVD intra reader variability was found to be 14 ± 
10%(r = 0.879).  
On the contrary, anti CD31 antibody also stained myeloid cells, lymphoid cells and 
megakaryocytes, in addition to the endothelial cells, thus resulting in high amount of 
nonspecific back ground staining.(34)  However, it becomes necessary to note that, when 
using the anti CD34 antibody, enumeration of the vessel density  often  becomes difficult 
when there is a high blast percentage obscuring the microvessels. 
Different investigators have made use of different guidelines and methods to quantitate the 
microvessel in the bone marrow. The most commonly used method is the “hotspot method”.  
In this method, after immunostaining with the antibody, the entire section is initially screened 
under low power magnification (40x) and 5 or 10 spots with the highest amount of 
microvessels are marked. These five fields, termed the microvessel hotspots are examined 
under the high power magnification (400x) and the number of vessels per high power field is 
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counted by a minimum of two observers to reduce the inter-observer variability. The final 
count on the degree of microvessel density of the entire marrow is given as the average count 
of microvessels in these five fields or the five hotspots. Several studies have reported the 
MVD by the above mentioned “hotspot” method for assessing microvessel density not only 
in cases of MDS but also in other haematological malignancies such a multiple myeloma and 
chronic lymphocytic leukaemia. (35)(36) 
Similarly, Lundberg et al demonstrated a higher degree of microvessel density in patients 
with MDS compared to healthy controls. In this study, the degree of angiogenesis neither 
correlated between various subgroups of MDS nor with the overall survival of the 
patients.(37) 
 
SCREENING FOR MYELODYSPLASTIC SYNDROME THROUGH THE 
AUTOMATED CELL ANALYSER: 
 
The diagnosis of myelodysplatic syndrome (MDS) requires a high index of suspicion by the 
clinician. The cause of peripheral cytopenia(s) may be due to  myriad haematological and non 
haematological factors. Although there are a number of previously described and documented 
morphological features of dysplasia, the assessment of these features in the peripheral blood 
smears and bone marrow aspirate smears is subjective and is labour intensive. 
Evaluation of the dysplastic features in the light microscopy in peripheral blood films is 
influenced by a variety of factors such as the pH of the stain, quality of staining, the time 
interval between collection and preparation of the smears, interobserver variation and 
morphological alterations due to secondary causes such as drugs and storage artefacts. 
 
38 
 
Automated haematology analysers such as Sysmex, Beckman Coulter system etc.have 
become an integral part of any modern laboratory. The result obtained from these analysers in 
routine laboratory setting is the complete blood count (CBC) which gives a quantitative 
assessment of the Haemoglobin, total leucocyte count, differential leukocytecounts and the 
platelet count.   
The automated haematology analysers use various analytical principles to quantitate blood 
cells in a peripheral blood sample and to perform a differential count.  The principle used by 
these analysers is known as the Coulter Principle.  
 
COULTER PRINCIPLE: 
 
A suspension of blood cells is passed through a small orifice simultaneously in the presence 
of an electric current. The individual blood cells passing through the orifice introduce an 
impedance change in this orifice which reflects the size and the number of cells.  
The Coulter method accurately enumerates and sizes the cells by detecting and measuring 
changes in the electrical impedance when a cell passes through the orifice or a small aperture. 
Particles such as blood cells are nonconductive but are suspended in an electrically 
conductive diluent. As each cell passes through the aperture, it momentarily increases the 
resistance of the electrical field between the submerged electrodes located on either side of 
the aperture. This is recorded as an electronic pulse.  The number of pulses indicate particle 
count and the size of the electrical pulse is proportional to the cell volume. This is based on 
the principle of impedance counting. 
This mechanism of impedance counting is useful to separate the major groups of cell lines 
such as erythrocytes, leukocytes and platelets. The estimation of the number and the volume 
is also possible based on the Coulter principle. For further sub classification of white blood 
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cells into neutrophils, eosinophils, basophils, monocytes and lymphocytes, the internal 
structure of these cells need to be accessed as they differ in their cytoplasmic granule content 
and nuclear complexity. 
For the purpose of measuring the internal complexity of cells the ability of these cells to 
scatter light was exploited. A focused stream of cells is interrogated by a laser beam directed 
against them. The cells in turn scatter light depending on their surface and their internal 
structure. The scattered light is in turn measured to assess the cytoplasmic content and 
nuclear complexity  by the principle of flowcytometric counting. 
Modern haematology analysers such as Beckmann Coulter DxH800, incorporate the above 
mentioned method of impedance counting and flow cytometric counting through the VCS 
technology.  
 
VCS TECHNOLOGY: 
 
A diluted blood sample is passed in a steady stream onto which a beam of laser light is 
focused. The WBC differential count is established by the automated cell counters using three 
measurements: the individual cell volume, conductivity and the light scatter by the individual 
cells. 
Volume: The leukocyte volume analysis is performed using the low frequency current.  This 
is based on the principle of impedance counting as described above.(Page 38) 
Conductivity: Cell walls of each cell act as conductors to high frequency current. The 
current detects differences in the insulating properties of the cell components, while passing 
through the cell walls and through the interior of the cell. The current characterises the 
granular and nuclear constituents and the chemical composition of the interior of the cell. 
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Light scatter: When a cell is struck by the coherent light of a laser beam, the light scatters 
and spreads out in all directions. Using detectors, the light scatter signals are collected to get 
information regarding the granularity of the cell, nuclear lobularity and the cell surface. The 
scattered light gives information regarding the cell structure, shape and the surface. Previous 
automated analysers such as LH 750 and 755 used only a single scatter measurement.  The 
UniCel DxH 800 cell counters have improved differential accuracy and efficiency of flagging 
by incorporating additional light scatter measurements such as UMALS, LMALS, LALS and 
AL.  This information is utilised to produce a scatter plot with a five part differential count. 
 
Out of the five different scatter measurements, LMALS is a side scatter and is considered to 
be a reliable indicator of the cell content and granularity.  The data obtained by the cell 
counters using the VCS technology is known as the Cell Population Data (CPD data). This 
CPD data is available in the instrument as separate values for volume, conductivity and 
scatter for each of the four major white blood cells which include neutrophils, lymphocytes, 
monocytes and basophils. The instrument utilises this information to calculate and provide a 
consolidated final WBC differential count.  
In addition to the peripheral leukocyte counts, these automated haematology analysers also 
show specific identifiable patters of cell population and distribution in the form of histograms 
and scatter plots. These patterns show specific alterations in various pathological conditions 
such as bacterial infections (38)(39)(40), malaria(41), chronic lymphoproliferative disorders 
(42), myocardial infarction(43) and few others.  These alterations have been shown to reflect 
the cellular changes seen in the light microscopy.  
For example, Lee et al demonstrated that mean cell volumes of neutrophils and monocytes 
can be used to identify patients with sepsis. Using Coulter LH750, they studied the mean 
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volumes of neutrophils and monocytes in 18 patients with sepsis, 38 patients with localised 
infections and 29 healthy controls. The mean neutrophil volume and the mean monocyte 
volume were found to be significantly higher (p-value = 0.000 for both) in patients with 
sepsis compared to those with localised infections and healthy controls. The mean cell 
conductivity and the lower median angle light scatter were significantly lower in the group 
with sepsis in comparison with those with localised infections and healthy controls (P-value 
0.029 and 0.022 respectively).(44) 
Several studies are being done at present, to determine if data from the automated 
haematology analysers can be reliably used as a screening or a diagnostic tool for the 
identification of myelodysplastic syndrome (MDS) in the routine clinical setting. (45) 
Initial attempts in the identification of cases of MDS through the peripheral blood samples by 
an automated haematology analyser were performed as early as 1987 when Rappaport et al, 
reported differences in the cell counter values in 5 cases of MDS when compared to the 
normal individuals.  (46) 
.A research paper published in the journal of clinical chemistry and laboratory medicine by 
Elisabeth et al, in 2008 showed that research population data from the automated cell counter 
could be routinely used to screen for myelodysplastic syndrome and chronic lymphatic 
leukaemia.(47)In this study, blood samples from 44 cases of chronic lymphatic leukaemia, 19 
cases of myelodysplatic syndrome and 199 healthy blood donors were analysed using the 
Beckman Coulter LH750. 
The mean and standard deviations of the volume, conductivity and scatter of the neutrophils 
were analysed in the 19 cases of MDS and all the healthy controls. The research population 
data turned out to be significantly different among the groups. The standard deviations of the 
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neutrophil conductivity was found to be predictive for myelodysplastic syndromes. 
(sensitivity 88.6%, specificity 84.4%).(47) 
The role of two neutrophil parameters namely, NEUT-X and NEUT-Y (Sysmex XE-2100) in 
the diagnosis of MDS was studied by Goel et al. NEUT-X is the measurement of side scatter 
diffraction and represents the internal structure of the neutrophils. This correlates with the 
hypogranularity of the neutrophils which is seen in MDS. This study included four groups, 
namely: 1. Controls 2. MDS 3. MPN 4. Megaloblastic anaemia. The mean value of NEUT-X 
was found to be significantly lower in MDS compared to the controls. On the contrary, the 
mean value of NEUT-X was significantly higher in  cases of megaloblastic anaemia.(48) 
A recent study by Raess et al demonstrated that cases of MDS have significantly decreased 
haemoglobin, haematocrit, WBC count and platelet counts compared to normal controls. In 
addition, patients with MDS had an elevated MCV, MCH, RDW and PDW compared to the 
normal controls. (45) Automated blood counts showed decreased percentage of neutrophils 
and corresponding increase in the percentage of the lymphocytes in cases of MDS.  
The differences in individual CPD parameters for neutrophils, lymphocytes and monocytes 
between MDS and control cases were not significant.  But, mean conductivity showed lower 
values in cases with MDS, suggesting a possibility of differences in the internal composition 
of leucocytes. The standard deviation of neutrophil volume also had a trend towards being 
elevated in cases of MDS. (45) 
In addition, Raess et al have developed a random forest classifier method that will help in the 
identification of patients having MDS with relatively high sensitivity and specificity. They 
proposed the applicability of this random forest classifier to discriminate cases of MDS from 
non MDS patients.  The sensitivity of the classifier was found to be 85% and the specificity 
was 87.1%.  By using the classifier, the most discriminating factors between the controls and 
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the MDS patients were mean neutrophil conductivity, mean neutrophil volume and the 
standard deviation of the neutrophil volume. In the standard conditions, the automated cell 
analyser flagged only 25% cases of MDS for subsequent peripheral blood examination, 
whereas the random forrest classifier identified 85% of patients with MDS. 
Further prospective studies to evaluate the importance of automated haematology analyser is 
necessary before it can be used on a routine basis for the identification of MDS in current 
situation. 
 
THERAPY RELATED MYELODYSPLASTIC SYNDROME: 
 
This form of myelodysplastic syndrome (t-MDS) occurs as a late complication of prior 
administration of cytotoxic drugs and radiation therapy for haematological or non-
haematological neoplasms.  
This category of MDS is considered under the broad heading of therapy related myeloid 
neoplasms by the WHO classification. The other disorders that are present under these group 
of neoplasms are t-MDS/MPN and t-AML. These three categories are diagnosed based upon 
the degree of dysplasia and the number of blasts. However, all of these therapy related 
neoplasms are best considered a single clinical entity. (1) 
The common cytotoxic agents implicated in therapy related myeloid neoplasms are 
Alkylating agents ( melphalan, cyclophosphamide, busulfan ), Topoisomerase type II 
inhibitors (Etoposide, doxorubicin, daunorubicin), antimetabolites, antitubulin drugs 
(vincristine, vinblastine) and ionising radiation therapy.  
Any age group may be affected. Generally, two subsets of patients are recognised. The first 
being t-MDS or t-MDS/t-MPN who present with bone marrow failure and peripheral 
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cytopenia(s). The second subset being t-AML/t-MDS or t-AML/t-MDS/t-MPN. The second 
subset of patients comprise about 20 to 30% cases and present with an overt leukaemia 
without the prior myelodysplastic phase with a very short or no myelodysplastic phase.  
The majority of patients have multilineage dysplasia. Anaemia is almost always present with 
evidence of macrocytosis and poikilocytosis in the peripheral smear. Neutrophils particularly 
show nuclear hypolobation and cytoplasmic hypogranularity. Dysmegakaryopoiesis is also 
seen in the form of pawn ball megakaryocytes, mono or hypolobated forms.  Almost 50% of 
the patients have lesser than 5% blasts in the bone marrow.  
Approximately 70% of patients with t-MDS harbour unbalanced chromosomal aberrations 
involving chromosomes 5 and 7.  The prognosis of t-MDS is generally poor. The survival is 
strongly influenced by the nature of the karyotypic abnormality and the underlying 
malignancy for which the cytotoxic therapy was administered.  
 
MANAGEMENT: 
 
The treatment for MDS is aimed at controlling symptoms, improving the quality of life and to 
prevent the progression of disease to leukaemia. Three agents have been approved by the 
FDA in the treatment of MDS, namely 5-azacytidine, Decitabine and Lenalidomide. The 
latter is used only in the treatment of 5q deletion syndrome. Stem cell transplantation 
particularly in younger patients offers the potential for curative therapy. 
Red cell transfusions are a major part of supportive therapy for patients with anaemia. Due to 
the repeated transfusions, patients develop iron overload and its metabolic consequences. Iron 
chelators are used to overcome this problem. 
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Drugs which inhibit angiogenesis have also been found to be useful in the treatment of MDS. 
As mentioned above, studies have documented the presence of an enhanced degree of MVD 
in the bone marrow microenvironment of patients with MDS. Generally, endothelial cells are 
considered to be more genomically stable compared to the genetically unstable cancer cells. 
Here lies the advantage of targeting endothelial cells instead of the cancer cells which rapidly 
acquire new mutations that confer rapid drug resistance to the conventional chemotherapeutic 
drugs. 
 
In summary, myelodysplastic syndromes are clonal hematopoietic stem cell neoplasms with a 
high propensity to transform into acute leukaemia. Patients with MDS almost always present 
with clinical symptoms manifested as a consequence of peripheral blood cytopenia(s). The 
peripheral cytopenia(s) are due to apoptosisof the  marrow progenitor cells resulting in  
ineffective haematopoiesis. MDS can be a primary denovo disease or secondary due to 
cytotoxic drugs. The peripheral blood smear and bone marrow show several pathological 
cellular and stromal alterations.  The cellular alterations manifests as dysplasia in the bone 
marrow progenitor cells and is reflected in the peripheral blood as cytopenia and abnormal 
cell morphology. The stromal alterations is usually in the form of increased reticulin fibrosis. 
MDS has been further subtyped based on their clinical, morphological, immunological and 
cytogenetic profiles by the WHO. IPSS score is used by the clinician to stratify patients into 
three risk categories. Several studies are being done at the cellular and molecular levels to 
gain a better understanding of the complex pathological alteration of these group of disorders.  
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RESEARCH AIMS AND OBJECTIVES 
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THE RESEARCH AIMS: 
1.  To study the cellular alterations in cases of MDS. 
2. To study the stromal vascular changes in cases of MDS. 
 
 
THE RESEARCH OBJECTIVES: 
 
1. To evaluate the role of cell population data (CPD) values obtained through the 
automated haematology cell counter (Beckman Coulter DxH800) in the diagnosis 
ofMDS . 
2. To look for differences in the CPD values among the MDS cases, non MDS cases and 
healthy controls.  
 
3. To enumerate the Microvessel Density (MVD) in the bone marrow trephine biopsy of 
patients with MDS, using anti CD34 antibody. 
 
4. To compare the values of MVD between MDS cases and controls. 
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MATERIALS AND METHODS 
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METHODOLOGY: 
 
This study was approved by the Institutional review board of the Christian Medical College, 
Vellore.  
The study spanned a period of 14 months from the 1
st
 of May 2013 to the 30
th
 of June 2014 
EPIDEMIOLOGICAL METHOD:  Analytical epidemiology – Comparative study. 
 
SELECTION OF CASES:  
 Diagnostic criteria: All the cases of primary (denovo) MDS diagnosed in the study period. 
The diagnosis was based upon clinical data, routine peripheral blood counts, 
examination of peripheral blood film, bone marrow study and cytogenetic analysis. 
 
 Eligibility criteria: Only the newly diagnosed cases in the specified study period were 
included. Old cases of MDS on follow up and cases of secondary MDS were excluded.There 
were a total of 124 cases of MDS diagnosed in the Christian Medical College and 
Hospital during this period. Out of the 124 cases of MDS recorded, 111 were primary 
(denovo) MDS and 13 cases were either on treatment or therapy related. 
Consequently, only the data obtained from the 111 cases of primary (denovo) MDS 
are discussed below. 
 
Sources of the cases: All the 111 cases included in the study were patients who visited the 
Christian Medical College Hospital in the specified study period. 
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SELECTION OF CONTROLS: 
As the study had two aims, the numbers and character of the controls were selected separately 
according to the objective. 
For the purpose of assessment of the CPD, two sets of controls were used in the study. One 
set consisted of 155 patients with illnesses other than MDS. These 155 non MDS controls 
were age matched and selected from the same source as the cases. The second set of 
controlswere 98 healthy blood donors with no present illness. The collection and processing 
of the peripheral blood samples of both the controls and cases were identical. 
For the purpose of assessment of the MVD in the trephine biopsies, 35 age matched controls 
were chosen. These controls were patients who had undergone bone marrow biopsies as a 
part of staging for other haematological and non haematological malignancies and were 
found to be free of marrow involvement. 
DATA COLLECTION: 
These necessary study parameters and data for these 124 cases were retrospectively collected 
from the department archives.  
 
Figure 4: Distribution of cases in the study period(May 2013 to June 2014). 
. 
Myelodysplastic 
syndrome(MDS) in study period 
(May 2013 to June 2014) 
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The demographic and the clinical information of the cases were collected from the electronic 
medical records. 
Out of the 111 cases included in the study, the CPD values were available for 68 cases. These 
68 cases were compared with 155 non MDS samples and blood samples from 100 healthy 
blood donors. The non MDS group consisted of those cases, who were being treated in 
various departments in the hospital as an outpatient or as in patient and did not have 
peripheral blood cytopenia(s) or other diagnosed haematological disorders. 
The 155 samples from the non MDS cases and 100 cases from normal healthy blood donors 
were processed in the same manner as followed for the MDS samples. 
Secondly, out of the 111 cases, the paraffin embedded tissue blocks were available for 107 
cases. The originally stained slides at the time of diagnosis and the blocks were collected 
from the archives. Immunohistochemistry was performed on the paraffin embedded blocks 
with anti CD34 antibody. 
 
COLLECTION OF THE CELL POPULATION DATA: 
 
The CPD parameters for the cases were collected from the Beckman Coulter DxH800 
automated haematology analyser. This is a high volume, fully automated haematology 
analyser which is capable of analysing upto 100 sample/ hour. The analyser makes use of the 
Coulter principle, optical detection and radiofrequency conductivity for cell counts and 
differential counts. This analyser provides a CBC, 5 part WBC differential count, reticulocyte 
count and NRBC counts from 165uL of blood sample.  
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The specimens were peripheral blood samples collected with dipotassium EDTA as 
anticoagulant. The samples were placed in the room temperature and processed within 2 
hours of collection from the patient, thereby excluding any effects of delayed processing. 
The CPD data were retrospectively collected form the MDS cases after a diagnosis of MDS 
was made by the examination of the peripheral blood film and the bone marrow. Only the 
first sample from each patient during the study period was used for the analysis in patients 
who had frequent CBCs. 
The CPD parameters that were compared between the three groups include the neutrophil 
volume, neutrophil conductivity, lymphocyte volume, lymphocyte conductivity, monocyte 
volume, monocyte conductivity, eosinophil volume, eosinophil conductivity. Lower medial 
angle light scatter (LMALS) for neutrophils, lymphocytes, monocytes and eosinophils.These 
parameters were periodically checked as a part of routine QC program and maintained within 
acceptable limits using Levey-Jennings charts and appropriate Westgard rules. 
 
IMMUNOHISTOCHEMISTRY IN THE BONE MARROW TREPHINE 
BIOPSY: 
ANTI-CD34 MONOCLONAL ANTIBODY: 
 
The antibody used was anti-CD34 monoclonal mouse IgG1 antibody. This antibody 
recognises a glycosylated type I 110-kDa transmembrane molecule which is considered to be 
a marker for the blood vessel endothelium.  
 
The sections were deparaffinised and rehydrated in graded series of alcohol. The sections 
were then labelled using an automated immunostaining procedure (Ventana medical 
systems). The antigen retrieval was performed by boiling at 95 to 100 C.  The mouse 
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monoclonal anti-CD34 (Dako, clone 96 3820 B; 1:10 dilution) was incubated for 60 minutes 
at 42 C. Followed by this, the sections were then incubated with the universal anti-mouse Ig 
biotinylated secondary antibody for 16 minutes at 37C.  
This was followed by incubation with the avidin-biotin-horseradish peroxidase (HRP) 
complex with the Ventana Medical Systems DAB detection kit for 8 min at 37C. The final 
revelation system used HRP-DAB as the final chromogen. Positive controls were bone 
marrow sections from patients with acute leukaemia. The slides were counterstained with 
hematoxylin. 
 
ENUMERATION OF THE MICROVESSEL DENSITY (MVD): 
 
Enumeration of the MVD in the bone marrow trephine biopsy sections was performed using 
the “hotspot” method. The bone marrow sections immunostained with anti-CD34 antibody 
was initially screened with the low power objective (4x) to identify hotspots which contained 
the maximum number of vessels. Five such hotspots were chosen by scanning the marrow 
section in the low scanning magnification (4x). These five areas or “hotspots” with the 
maximum microvessel density were thenexamined with the high power objective (40x). The 
number of vessels within each of these five hotspots with maximum density were counted. 
The MVD value of the particular marrow sample was given as the mean MVD of the five 
counted fields.  
The hotspots were identified by two observers individually. If different hotspots were 
identified, the observers had to decide on which one was used for assessing the MVD in the 
five consecutive fields. 
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STATISTICAL METHODS: 
 
 Data was analysed using the statistical package for Social sciences (SPSS) software, 
Windows version 16. 
 
 Association of the CPD values between the different sub groups (MDS, non MDS, 
healthy donors) was calculated using the analysis of variance (ANOVA). 
 
 Association of the bone marrow MVD between the MDS cases and controls was 
calculated using the Independent sample t-test. 
 
 P values < 0.05 were considered significant. 
 
 Sensitivity and specificity values were calculated using the ROC curves. 
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DATA ANALYSIS 
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ANALYSIS OF DATA: 
DEMOGRAPHICS: 
 
A total number of 111 caseswere included in the study. 
Out of the total 111 patients, there were 74 (66.6%) malesand 37 (33.3%) females. 
The youngest patient was 3 years old and the oldest was 78 years old with a median patient 
age of58.5 years. 
 
Table 5: Distribution of cases by gender. 
Gender Number 
Male  74 (66.6%) 
Female  37(33.3%) 
Total 111 (100%) 
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Figure 5: Age wise distribution of MDS cases. 
 
Table 6:  Distribution of cases according to the WHO subtypes. 
WHO category Number of cases. 
Refractory anaemia with excess blasts-I 19 (17.1%) 
Refractory anaemia with excess blasts-II 21 (18.9%) 
MDS-F 2(1.8%) 
Refractory cytopenia with multilineage 
dysplasia 
4(3.6%) 
Refractory  cytopenia with unilineage 
dysplasia 
34(30.6%) 
Isolated 5q deletion syndrome 6(5.4%) 
Refractory anaemia with ringed sideroblasts 6(5.4%) 
MDS-Unclassifiable 7(6.3%) 
Childhood myelodysplastic syndrome 2(18%) 
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The 111 cases of MDS were classified into low grade and high grade based on the blast 
percentage for the purpose of further analysis. 
Bone marrow blast count of < 5% was taken as low grade and 5 or more was considered high 
grade. There were 44(39.6%) cases of high grade MDS and 67 (60.3%) cases of low grade 
MDS. 
Table 7: Distribution of cases by grade. 
Category of MDS Number of cases 
Low grade 67 (60.3%) 
High grade 44 (39.6%) 
Total 111 cases (100%) 
 
COMPARISON OF CELL POPULATION DATA AMONG MDS CASES, NON 
MDS AND NORMALCONTROLS (HEALTHY BLLOD DONORS): 
 
Among the 111 cases included, the cell population data from the automated cell counter was available 
for 68 cases.  
Consequently, the data of these 68 cases was compared with 155 non MDS samples and with 98 
healthy blood donors. 
The CPD parameters of neutrophils, lymphocytes, monocytes and eosinophils were separately 
compared among the three groups. 
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Table 8: Comparison of the CPD parameters for neutrophils among MDS and non MDS patients: 
 
NEUTROPHILS MDS cases 
(n-68) 
NON MDS 
cases 
(n-155) 
p-
value 
 Mean(SD) Mean(SD)  
VOLUME 153.76(16.44) 147.08(5.93) 0.000 
CONDUCTIVITY 144.74(6.32) 147.68(4.87) 0.000 
SCATTER 125.28(14.42) 136.94(6.19) 0.000 
    
*p value is significant when <0.05 
 
 
 
 
Table 9: Comparison of the CPD parameters for neutrophils among MDS and healthy donors. 
 
NEUTROPHILS MDS cases 
(n-68) 
Donors 
 (n-98) 
p-value 
 Mean(SD) Mean(SD)  
VOLUME 153.76(16.44) 148.90(5.32) 0.002 
CONDUCTIVITY 144.74(6.32) 145.61(2.46) 0.704 
SCATTER 125.28(14.42) 132.88(5.87) 0.000 
*p value is significant when <0.05 
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Figure 6: ROC curve for neutrophil volume. 
By assigning the cut off value for mean neutrophil volume as 146.50, the sensitivity was 
found to be 70.6% and the specificity was 47.7%. 
 
Figure 7: ROC curve for neutrophil scatter. 
By assigning the cut off value for mean neutrophil scatter as 129.50, the sensitivity was found 
to be 90.3% and the specificity was 57.4%. 
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Table 10: Comparison of the CPD parameters for lymphocytes among MDS and non MDS patients: 
 
LYMPHOCYTES MDS cases 
(n-68) 
NON MDS 
cases 
(N-155) 
P value 
 Mean(SD) Mean(SD)  
VOLUME 90.84(8.70) 86.24(4.17) 0.000 
CONDUCTIVITY 116.93(7.20) 117.37(4.23) 1.000 
SCATTER 59.59(9.30) 60.83(4.59) 0.358 
*p value is significant when <0.05 
 
 
Table 11: Comparison of the CPD parameters for lymphocytes among MDS and non MDS patients: 
 
LYMPHOCYTES MDS cases 
(n-68) 
Donors 
 (N-98) 
p-value 
 Mean(SD) Mean(SD)  
VOLUME 90.84(8.70) 84.57(2.81) 0.000 
CONDUCTIVITY 116.93(7.20) 115.71(1.72) 0.273 
SCATTER 59.59(9.30) 58.806(1.99) 1.000 
*p value is significant when <0.05 
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Table 12: Comparison of the CPD parameters for monocyte among MDS and non MDS patients: 
 
MONOCYTES MDS cases 
(n-68) 
NON MDS 
cases 
(n-155) 
p-value 
 Mean(SD) Mean(SD)  
VOLUME 176.43(16.06) 165.66(7.621) 0.000 
CONDUCTIVITY 124.76(7.904) 125.60(4.22) 0.711 
SCATTER 75.82(10.18) 75.83(5.03) 1.000 
*p value is significant when <0.05 
 
 
Table 13: Comparison of the CPD parameters for monocyte among MDS and healthy donors: 
 
MONOCYTES MDS cases 
(n-68) 
Donors 
 (n-98) 
p-value 
 Mean(SD) Mean(SD)  
VOLUME 176.43(16.06) 164.80(5.41) 0.000 
CONDUCTIVITY 124.76(7.904) 122.47(2.35) 0.009 
SCATTER 75.82(10.18) 70.45(5.88) 0.000 
  *p value is significant when <0.05 
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Figure 8: ROC curve for monocyte volume. 
 
By assigning the cut off value for mean monocyte volume as 166.50, the sensitivity was 
found to be 73.5% and the specificity was 60.0%. 
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Table 14: Comparison of the CPD parameters for eosinophils among MDS and non MDS patients: 
 
EOSINOPHILS MDS cases 
(n-68) 
NON MDS 
cases 
(n-155) 
p-value 
 Mean(SD) Mean(SD)  
VOLUME 154.95(22.61) 156.79(7.81) 0.907 
CONDUCTIVITY 152.63(15.83) 150.39(9.28) 0.355 
SCATTER 176.87(16.58) 185.50(5.42) 0.000 
  *p value is significant when <0.05 
 
 
Table 15: Comparison of the CPD parameters for eosinophilsamong MDS and non MDS patients: 
 
EOSINOPHILS MDS cases 
(n-68) 
Donors 
 (n-98) 
p-value 
 Mean(SD) Mean(SD)  
VOLUME 154.95(22.61) 158(6.04) 1.000 
CONDUCTIVITY 152.63(15.83) 148.36(2.87) 0.340 
SCATTER 176.87(16.58) 184.22(4.77) 0.799 
  *p value is significant when <0.05 
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Figure 9: ROC curve for eosinophil scatter. 
 
By assigning the cut off value for mean eosinophil scatter as 180.50, the sensitivity was 
found to be 90.3% and the specificity was 63.2%. 
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Table 16: Comparison of CPD data among the low grade and high grade cases of MDS. 
 
CPD PARAMETERS MDS p-value 
LOW GRADE 
 
HIGH GRADE 
NEUTROPHIL  
Volume (±SD) 151.32 (15.967) 156.68(16.784) 0.183 
Conductivtiy (±SD) 146.65(5.663) 142.45(6.397) 0.006 (p-val <0.05) 
Scatter(±SD) 127.68(11.846) 122.42(16.749) 0.135 
LYMPHOCYTES  
Volume(±SD) 89.57(6.902) 92.35(10.378) 0.191 
Conductivity(±SD) 118.05(3.944) 115.58(9.695) 0.160 
Scatter(±SD) 59.84(7.049) 59.29(11.559) 0.811 
MONOCYTES  
Volume(±SD) 174.16(14.673) 179.13(17.439) 0.207 
Conductivity(±SD) 126.38(5.992) 122.84(9.455) 0.065 
Scatter(±SD) 74.86(8.638) 76.97(11.817) 0.401 
EOSINOPHILS  
Volume(±SD) 156.08(12.939) 153.61(30.628) 0.678 
Conductivity(±SD) 152.19(14.281) 153.16(17.750) 0.803 
Scatter(±SD) 176.32(13.544) 177.52(19.832) 0.770 
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ASSESSMENT OF THE MICROVESSEL DENSITY AND COMPARISON 
BETWEEN MDS PATIENTS AND CONTROLS: 
 
Out of the total 111 cases included in this study, the paraffin embedded tissue blocks were 
available for 107 cases. The remaining 4 cases were slides for review that was referred from 
outside hospital and hence blocks were not available. The MVD was calculated in the 
remaining 107 cases. 
Among the 107 cases, in 6 cases, there was no positive staining of endothelial lined vessels 
using anti CD34 antibody even after repeat staining. Hence these 6 cases were considered 
inconclusive for the enumeration of MVD.  Consequently, only the results obtained from the 
101 cases are discussed throughout the study.  
The age distribution ranged from 3 years to 78 years. Among the 101 cases, 68 were males 
and 33 were females. 
Microvessel density(MVD): 
Table 17: The mean MVD of MDS cases and controls. 
 Micro Vessel Density 
(per high power field 40X) 
 
p-value 
MEAN SD  
0.000 MDS patients (101) 8.836 5.961 
Controls (35) 5.531 2.502 
The microvessel density (MVD) is significantly different between MDS cases and controls 
with a t statistic of 4.536 and p-value of 0.000. 
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Table 18:   Mean MVD in controls andamong different WHO subtypes 
 Number of subjects Mean MVD per high 
power field 
Controls 35 5.531  
RAEB-I 20 10.36 
RAEB-II 17  8.411 
MDS-F 2 14.5 
RCUD 4 10 
RCMD 30  8.866 
5q deletion 6 4.733 
RARS 5 7.6 
Hypoplastic MDS 8 7 
MDS-U 7 10.82 
Childhood MDS 2 4.5 
 
Cellularity and MVD: 
The cellularity of the marrow was assessed subjectively and was classified as hypercellular, 
normocellular and hypocellular for the respective ages. 
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Among the 101 cases, 74 cases had hypercellular, 8 cases had normocellular and 19 cases had 
hypocellular bone marrows respectively. 
 
Figure 10: Distribution of cellularity of bone marrow among MDS patients. 
The mean MVD was higher in cases with hypercellularity of the marrow. 
Table 19: Comparison of bone marrow cellularity and MVD: 
Cellularity                        MVD (per high power field 40x) 
 Mean  SD 
Hypercellular 9.824 6.5565 
Normocellular 6.200 3.0817 
Hypocellular 6.095 2.0853 
 
 
73% 
8% 
19% 
Cellularity 
Hypercellular Normocellular Hypocellular
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Blast percentage and MVD: 
Table 20: Comparison of blast percentage and MVD: 
MDS cases                                  MVD p-value 
Mean SD  
0.287 Low grade 8.277 4.6976 
High grade 9.723 7.5347 
 
Based on the blast percentage, the cases were classified as low grade and high grade. There 
were 62 low grade cases and 39 high grade cases. There was no significant difference in the 
MVD between the low and high grade cases. 
The vessels that were observed showed  differences in the morphological patterns.  
The different morphological patterns include: 
1.  Vessels that were more or less straight in shape with focal branching and a small visible 
lumen. These vessels had a uniform linear staining of endothelial cells by CD34 antibody. 
2. Large vessels with visible lumina and irregular, branching shapes. 
3. Sinusoid like vessels. 
4. Small vessels without a visible lumen which appeared to be like “endothelial sprouts” 
However, there was a mixture of all these patterns in a given case and did not have any 
relation to the type or cellularity of the marrow. 
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Fig 11: Hypercellular marrow in a case of MDS (a) showing marked erythroid hyperplasia (b) 
and an increased reticulin content (c).  
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Figure 12:  Megakaryocyte hyperplasia and dysmegakaryopoiesis – an example of cellular 
alterations seen in MDS.(20x, H&E) 
 
 
 
Figure 13: Paratrabecular immature erythroid colonies – an example of stromal alterations 
seen in MDS.(40x, H&E) 
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Figure 14:  Mildly hypercellular marrow from a 56 year old male patient without MDS 
. (20x, H&E) 
 
 
Figure 15: The corresponding IHC (anti CD34) section of the field in fig 14 showing only 
few thin linear vessels in the paratrabecular location. (arrow heads) (20x) 
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Fig 16:  High power view of a linear thin walled patent capillary in a patient 
 without MDS. (40x, H&E) 
 
 
 
Fig 17: Anti CD34 immunostained sections of the corresponding field in Fig 16 (40x) 
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Figure 18: A case of MDS with increase in microvessel density (MVD). (10x, H&E) 
 
 
 
Figure 19: The corresponding field in Figure18 immunostained with anti CD34 antibody 
demonstrate an increase in the MVD. (10x) 
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Figure 20:  Irregularly dilated endothelium lined vessels. (40x, antiCD34) 
 
 
 
 
Figure 21:  A single linear microvessel which shows immunostaining with anti CD34 
antibody. (40x) 
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Figure 22: Sinusoid like vessels with dilated, irregular lumen. (40x, anti CD34) 
 
 
 
Figure 23: Small endothelial sprouts with no visible lumen and strong immunoreactivity for 
anti CD34 antibody. (40x) 
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Figure 24:  Two microvessels cut in cross section displaying a visible lumen and positively 
staining endothelial cells for anti CD34 antibody. (40x) 
 
 
 
Fig 25: A group of blasts which show a granular staining of the cytoplasm with antiCD34 
antibody. (40x) 
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Figure 26: A dysplastic monolobate megakaryocytes in a case of MDS RCMD. (40x, H&E) 
 
 
 
 
Figure 27:  Dysplastic megakaryocytes staining positive with antiCD34 antibody. (40x) 
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Figure 28:  Two developing myeloid cells (Neutrophils) in the marrow with marked 
pleomorphism in their cellular morphology. (100x, MGG) 
 
 
Figure 29:  Two developing myeloid cells (Neutrophils) in the marrow. One of the 
neutrophils (left side) shows features of dysplasia. (100x, MGG) 
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Figure 30:  Three monolobate megakaryocytes in the bone marrow aspirate of a case with 5q 
deletion syndrome. (40x, MGG) 
 
Figure 31:  Dysplastic megakaryocyte with two separate nuclear lobes in a case of MDS. 
(100x, MGG) 
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Figure 32:  Erythroid dysplasia identified by the presence of nuclear budding. (100x, MGG) 
 
 
Figure 33:  Megaloblastoid erythroid maturation in a case of MDS. (100x, MGG) 
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Figure 34:  A neutrophil in the peripheral smear of a patient with  bacterial infection.The 
cytoplasm contains toxic granules. (100x, MGG) 
 
Figure 35:  Hypogranular neutrophil in a patient with MDS. The neutrophil also shows the 
classic pseudo Pelger Huet anomaly seen in cases with MDS. (100x, MGG) 
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Figure 36:  The scatter plot of the 5 part differential WBC count in a case of MDS RCMD. 
The neutrophil population (pink dots) overlaps with the monocyte population (green dots) 
due to an increase in the size and decrease in granularity. 
 
 
Figure 37:  The cell population data of the same case of MDS RCMDfor which the scatter 
plots are shown in Figure 36. 
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Figure 38:  A dysplastic eosinophil in the bone marrow displaying nuclear hyperlobation. 
(100x, MGG) 
 
Figure 39:  An eosinophil in the bone marrow with hypogranularity in a case of MDS. (100x, 
MGG) 
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DISCUSSION: 
 
CELL POPULATION DATA: 
Myelodysplastic syndrome (MDS) is a clonal disorder, which affects the pluripotent hematopoietic 
stem cells. Hence the abnormal development is reflected in all the major cells lineages namely the 
erythroid, myeloid and the megakaryocytic lineages. Although there are well-documented features of 
dysplasia in the red blood cells and the platelets, the dysplastic changes are easily recognised and 
appreciated in the cells belonging to the myeloid series. This is partly because of the fact that the 
traditional staining procedure employed for staining of the peripheral blood film, using Romanowsky 
stains, imparts a differential staining to the white blood cells so that distinct identification of 
granulocytes such as neutrophils, eosinophils, basophils and agranulocytes such as monocytes and 
lymphocytes can be made based on the cytoplasmic staining, colour of granules and the nuclear 
features. In addition, the morphology of erythrocytes can be influenced by co-existing common 
conditions such as iron deficiency anaemia. The morphological changes observed in the peripheral 
blood smear arealso reliably reflected by automated cell counters, contributing to the generation of 
“suspect flags”. 
The five part differential counts of the white blood cells on the Beckman Coulter DXH 800automated 
haematologyanalyser is determined by the Volume, Conductivity and Scatter principle. The values 
measured by the cell counter in terms of size, conductivity and scatter corresponds to the light 
microscopic findings such as macrocytosis, differences in the granularity, nature of the granules and 
nuclear complexity respectively. This can be termed as “Machine morphology”. 
Apart from the traditional numerical counts of the blood cells (Complete Blood Counts or CBC), 
histograms and scatter plots are also provided by the automated cell counters. The patterns in the 
histograms and scatter plots can also be utilised to understand the distribution, size and property of the 
cells. The following part of the discussion enumerates the significant changes observed in this study 
and describes parameters that may assist in predicting patient samples with MDS. 
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In the present study, the cell population data was studied for the four major classes of leukocytes 
namely neutrophils, lymphocytes, monocytes and eosinophils. In human blood, neutrophils contribute 
to the major population of the white blood cells. Hence the search for an abnormality of the neutrophil 
series would be more rewarding and can be easily seen.The study showed a significant difference 
between the volume, conductivity and the scatter of the neutrophils between the MDS and the non-
MDS cases.  
 
 
Figure 40:  Difference in the mean neutrophil volume (MNV) between theMDS, non MDS and donor 
groups. 
 
COMPARISON OF CPD PARAMETERS OF NEUTROPHILS 
 
The mean neutrophil volume (MNV) in non MDS cases and the healthy blood donors were 147.08 
and 148.90 respectively. On the contrary, in MDS cases, there was an increase in the mean volume of 
neutrophils up to 153.76. This difference in volume of the neutrophils between cases of MDS in 
comparison to those of non MDS and the normal controls was statistically significant. (Fig : 40)   
There is ample evidence that the mean neutrophil volume is also higher is cases of megaloblastic 
anaemia(s) (MA) when compared to normal. This increase in the volume has been attributed to the 
fact that the maturationis characterised by nuclear-cytoplasmic asynchrony occurring in the marrow of 
patients with MA.The increase in the cell volume can also be attributed to the fact that there is nuclear  
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p-value: 0.000 p-value: 0.002 
p-value: 0.359 
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hypersegmentation in neutrophils. Patients with sepsis who manifest toxic changes in the neutrophils 
also have a high neutrophil volume.   
This increase in the mean neutrophil volume is possibly because of the presence of immature 
neutrophil precursors in the peripheral blood.  When there is a left shifted neutrophil maturation in the 
peripheral blood, the cell counter not only measures the mature neutrophils, but also the immature 
forms such as myelocytes, metamyelocytes which have a higher volume. This mechanism can be 
accounted for the increase in the mean neutrophil volume of patients with sepsis. (44) 
Patients with MDS also manifest a megaloblastoid maturation of the hematopoietic cells which is 
commonly seen in the erythroid series of cells and is reflected in the routine peripheral blood film as 
macrocytosis. Since the disorder is clonal,the neutrophils and other myeloid cells also undergo a 
megaloblastoid maturation similar to that seen in  red blood cell precursors. Immature neutrophil 
precursors such as myelocytes and metamyelocytes are also present in the peripheral blood of patients 
with MDS. Hence both these mechanisms might help us explain the increase in the mean neutrophil 
volume noted in the study. 
In cases of MDS, the neutrophils frequently exhibit features of cytoplasmic vacuolations similar to 
those in sepsis and in patients with reactive neutrophilia. The cytoplasmic vacuolations can also be 
considered a possible cause for the increase in the mean volume of neutrophils.  
Another possibility to entertain is, whether an increase in the MNV can be attributed to the 
mechanism of apoptosis.  This may be significant since peripheral cytopenia noticed in cases of MDS 
is ascribed to enhanced apoptosis in precursor cells. As per definition, apoptosis is classically 
associated with shrinkage in the volume of cell. (30)On the contrary, there is an increase in the MNV 
observed in this study. At this point, there is a need to highlight a newly discussed term 
”Necroptosis”.   
 
Necroptosis is a form of cell death that involves a mixture of processes seen in necrosis and apoptosis. 
Biochemically and morphologically, the process resembles necrosis. There is loss of ATP, cell 
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swelling, release of lysosomal enzymes and rupture of the plasma membrane.  But, unlike necrosis the 
stimulus for the cell death is triggered by genetically programmed signal pathways. In this manner, 
the process resembles apoptosis.  Because of the combination of both these features, necroptosis is 
sometimes called “programmed necrosis”.(30) 
This concept of necroptosis can also explain the changes in neutrophils found in this study. The 
increase in the neutrophil volume can be attributed to the cellular swelling before the programmed cell 
death is genetically initiated. The peripheral cytopenia can also be explained likewise. 
MEAN NEUTROPHIL CONDUCTIVITY (MNC): 
 
                     
 
Figure 41:  Difference in the neutrophil conductivity between the MDS, non MDS and the donor 
groups. 
 
Analysis of the data from the mean channel of neutrophil conductivity showed a significant 
decrease in the mean conductivity in MDS cases compared to the non MDS group (p-
value=0.000). But there was no significant difference in mean conductivity when compared 
with the normal donors. Also noteworthy was the fact that there was significant difference in 
the conductivity between the non MDS and the donor groups. From the values that have been 
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obtained, only the non MDS patients had a significant difference in the mean conductivity 
with both the groups.   
The non MDS group includes all patients with illnesses other than MDS. The illnesses 
include viral fever to solid tumours. Hence there is a high probability that the neutrophils of 
these group of patients might show evidence of toxic changes and a left shift in the 
maturation. Toxic changes in the neutrophils is characterised by increased number and 
density of the granules. This causes an increase in the conductivity of the neutrophils. 
Because of the hypogranularity in the neutrophils of MDS, there is a measurable decrease in 
conductivity.  
MEAN NEUTROPHIL SCATTER (MNS): 
 
 
Figure 42:  Difference in the mean neutrophil scatter between the MDS, non MDS and donor 
groups. 
 
In the case of neutrophil scatter, there were significant differences amongst all the three 
groups.  The difference in the content of granularity and the nuclear complexity are two 
important features reflected by the scatter values.  The mean neutrophil scatter values in 
MDS patients, non MDS patients and healthy donors were was 125.28,  136.94 and 132.88 
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respectively.  These values also reflect the pathology of MDS.  Hypogranularity seen in the 
neutrophils of MDS cases  isevidenced as a decrease in the mean neutrophil scatter values. 
 
COMPARISON OF CPD PARAMETERS OF LYMPHOCYTES 
 
The morphology of lymphocytes is not usually considered in the assessment of dysplasia in 
cases of MDS by light microscopy in the routine setting. Since the lymphocyte is agranular, 
the point of assessing any difference in the content of granularity does not hold goodwhen 
assessing for dysplasia. When compared to the other leukocytes, the size of lymphocytes is 
smaller with a relatively higher nuclear-cytoplasmic ratio. The nucleus of a lymphocyte 
shows little variation in size and shape when compared to neutrophils and eosinophils.  
 
This study showed a significant difference in the volume of lymphocytes of MDS cases when 
compared to the non MDS groups and healthy donors (p-value: 0.000 and 0.000 
respectively).  The mean lymphocyte volume in cases of MDS was increased at 90.84. This 
value is higher when compared to the non MDS groups and healthy donors who had mean 
lymphocyte volume of 86.24 and 84.57 respectively.  
 
The reason for an increase in the volume of lymphocytes is debatable.  It is possible that there 
is a minimal increase in the volume of lymphocytes in MDS. This increase in the volume 
might not be sufficient enough to be perceived at the light microscopic examination of the 
peripheral smear or the bone marrow.   
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MEAN LYMPHOCYTE VOLUME (MLV): 
 
 
Figure 43:  Difference in the mean lymphocyte volume (MLV) between the MDS, non MDS 
and donor groups. 
 
The figure shows that there is also a significant difference in lymphocyte volume between the 
non MDS and the healthy donors. This small difference in the volume can be explained by 
the presence of reactive lymphocytes in the non MDS cases. Reactive lymphocytes 
morphologically manifest an increase in the volume of cytoplasm as compared to normal.  
 
 
Figure 44:  Difference in the mean lymphocyte conductivity (MLC) between the MDS, non 
MDS and donor groups. 
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There were no significant differences in the mean lymphocyte conductivity (MLC) and the 
lymphocyte scatter (MLS) among the various groups of patients and controls. This is 
acceptable, as lymphocytes are agranulocytes. Hence, only the volume of lymphocytes 
appeared to be an important parameter to identify MDS. 
COMPARISON OF VCS PARAMETERS OF MONOCYTES 
 
Similar to the lymphocytes, monocytes are also agranulocytes. Even though certain authors 
claim that monocytes can have a fewer number of fine granules, the amount of granules in the 
cytoplasm of monocytes in negligible when compared to neutrophils and eosinophils. The 
most striking feature when assessing a monocyte is its size. The monocyte is the largest of the 
leukocytes in the peripheral blood. Hence changes related to the size of the monocytes may 
be easier to detectthan the changes in its cytoplasm and the nucleus.  
There are several causes of monocytosis in the peripheral blood which include infections, 
inflammatory conditions and primary hematopoietic neoplasms such as Chronic Myeloid 
Leukaemia, Acute monocytic leukaemia, myeloproliferative neoplasms and myelodysplastic 
syndromes. In monocytosis occurring as a part of the primary hematopoietic neoplasms, the 
monocytes are part of the neoplastic clone.   
In acute myelomonocytic leukaemia and acute monocytic leukaemias, the monocytes 
demonstrate marked immaturity whereas, more mature monocytosis is seen in cases of CML.  
Monocyte differentiation in the marrow passes through three stages, which include 
monoblasts, promonocytes and mature monocytes, although neither monoblasts nor 
promonocytes are identified in the normal marrow specimens. 
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Though monocytosis has been documented in MDS, the presence of circulating immature 
forms has not been completely studied. Unlike the neutrophils and eosinophils, definite signs 
of dysplasia in monocytes are not very clear. In this study, MDS cases recorded a mean 
monocyte volume (MMV) of about 176.43.  This value was significantly high when 
compared to the non MDS group and the healthy donors with a p-value of 0.000 and 0.000 
respectively.  
 
Mardi et al and Lee et al have demonstrated that there is a significant increase in the mean 
neutrophil volume and the mean monocyte volume in cases of sepsis. (49)(44)In this 
particular study, the authors have not discussed about the possible causes for their findings in 
cases of sepsis. Similar to the neutrophils, the monocytes also show vacuolations and few 
granules when activated. Thus, alike the neutrophilic series of cells, it is possible that the 
monocytes also show few immature precursors in the peripheral blood, the differences of 
which may not be identified at the light microscopy level. The presence of cytoplasmic 
vacuolations also may contribute to an increase in the volume. 
 
The other two CPD parameters of monocytes such as the conductivity and scatter were not 
significantly different when compared to the non MDS and the control groups. Thus, the 
volume was the only parameter that was significantly different among the three groups. 
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Figure 45:  Difference in the mean monocyte volume (MMV) between MDS cases, non MDS 
patients and donors. 
 
COMPARISON OF CPD PARAMETERS OF EOSINOPHILS 
Eosinophils are easily identified in the peripheral smear due to the fact that they have 
granules in the cytoplasm staining red orange by the conventionally used Romanowskny 
stains. In the normal healthy individual, they are similar in size to the neutrophils. In this 
study there was no statistically significant difference in the volume of the eosinophils 
between the MDS cases and the other groups. The mean eosinophil volume in cases of MDS 
was 152.96 and that of the non MDS groups and the donor group were 156.79 and 158 
respectively. However, the mean volume of the eosinophils  (MEV) was considerably lower 
in comparison with the non MDS groups and the healthy donor group.   
The values for conductivity in the eosinophils were also not significantly different amongst 
the groups. The values for eosinophil conductivity showed a minimal increase compared to 
the other two groups.  
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The only significantly different parameter, pertaining to the eosinophils, amongst the three 
groups was the mean scatter values (MES). The mean eosinophil scatter (MES) was 
decreased in cases with MDS compared to the non MDS and the donor group. 
 
 
Figure 46:  Difference in the mean eosinophil scatter (MES) between the MDS, non MDS 
and donor groups. 
 
As mentioned in the earlier discussions, the scatter values are greatly influenced by the 
granularity seen the cytoplasm of the cells. Similar to the neutrophils, eosinophils also show a 
decrease in the scatter values. The reason for the decrease in the scatter values can be 
attributed again to the hypogranularity seen in the eosinophils. It is known that a decrease in 
the granular content of the leukocytes is a feature of dysplasia in cases with MDS. Hence, 
similar to the neutrophils, the decrease in the granularity in the cytoplasm of the eosinophils 
can possibly explain the decrease in the mean eosinophil scatter values.  
In summary, the CPD parameters of neutrophils, lymphocytes, monocytes and eosinophils 
were compared between MDS cases, non MDS cases and healthy donors. There was a 
significant difference in the neutrophil volume (MNV), neutrophil conductivity (MNC), 
Eosinophil 
scatter 
MDS 
Cases 
Normal 
donors 
non 
MDS 
p-value: 0.000 p-value: 0.000 
p-value: 0.799 
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neutrophil scatter(MNS), lymphocyte volume (MLV), monocyte volume (MMV) and the 
eosinophil scatter (MES) between the MDS cases and the control groups.  
Out of these six parameters, the significance of lymphocyte volume and neutrophil 
conductivity is debatable since, these two parameters were found to be significant even 
between the non MDS cases and controls. This difference however can be explained with the 
fact that the non MDS category also comprises patients with various illnesses which can 
considerably alter the morphology of the blood cells.    
So only the rest four parameters namely neutrophil volume (MNV) and scatter (MNS), 
monocyte volume (MMV) and eosinophil scatter (MES) were considered to be of 
significance.  
TABLE 21:   Four significantly different CPD parameters in the study. 
CPD PARAMETER MDS 
(n-68) 
NON MDS 
(n-155) 
HEALTHY 
DONORS 
(n-98) 
Mean neutrophil volume 
(MNV) 
153.76 (Increased) 147.08 148.90 
Mean neutrophil scatter 
(MNS) 
125.28 (Decreased) 136.94 132.88 
Mean monocyte volume 
(MMV) 
176.43 (Increased) 165.66 164.80 
Mean eosinophil scatter 
(MES) 
176.87 (Decreased) 185.50 184.22 
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The following details can be understood from the table: 
1.  Both the granulocytes in the study, i.e the neutrophils and the eosinophils showed a 
significant difference in the scatter values compared to the other groups. 
2.  The monocyte being an agranulocyte, showed a significant difference only in the volume 
rather than the conductivity and scatter.  
The possible reasons for the findings in this study have been discussed in the preceding 
sections. In addition to these, the possibility of machine induced changes on the morphology 
of the blood cells should also be kept in consideration. The automated haematology analyser 
uses certain reagentssuch asErytholyse and Stabilise to lyse the red blood cells and platelets 
while performing a differential count on the white blood cells. An isotonic diluent solution is 
used to dilute the samples for counts and to provide sheath flow to achieve single cell stream 
for the VCS module to analyse the cells.The Stabilise solution prevents the lysis of the white 
blood cells and preserves them in the near normal morphology. The changes caused by these 
solutions may also alter the morphology of these cells by their actions on the plasma 
membrane and cytoplasm. These changes might be also influenced by the on going cellular 
changes of apoptosis.  Therefore, the CPD parameters may be a reflection of the net effect of 
the disease associated change added with the reagent induced changes in the analyser. 
 
MICROVESSEL DENSITY IN THE BONE MARROW: 
 
Angiogenesis or the formation of new vesselshas an important roleto play in tumour growth 
and dissemination.Development of angiogenesis has a prognostic impact in various solid non 
haematological tumours such as breast carcinoma. Several observers have hypothesized  that 
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the growth potential of primary solid tumours is strictly based on their ability to induce 
angiogenesis from the surrounding vasculature. The basic reason for this tumour induced 
neovascularisation is obvious and represents the increased demand of the proliferating 
tumour cells for more nutrition. Thus an increased vessel density in the tumour bed could be 
an indirect evidence that reflects the growth potential of the neoplastic cells. 
The stimulus for the formation of new vessels is mainly produced by the neoplastic clone of 
tumour cells themselvesand their interaction with the surrounding stroma.Molecules such as 
VEGF and bFGF are proangiogenic and are produced by the tumour cells. The most likely 
stimulus, which triggers the production of these proangiogenic molecules by the tumour cells, 
is tissue hypoxia. The rapidly proliferating tumour cells are deprived of oxygen in the 
immediate vicinity. 
Long standing hypoxia in the tumour microenvironment upregulates the production of 
Hypoxia induced factor alpha (HIFa) by the tumour cells.The HIFa molecule is a strong 
stimulus for the production of pro-angiogenic molecules, which compensate for the tissue 
hypoxia by alterations in the calibre of blood vessels and formation of new vessels.  
Apart from the solid tumours, hematopoietic neoplasms which may be loosely designated as    
“liquidtumours” are also capable of neovascularisation. One of the early evidence for the 
presence of enhanced angiogenic activity was documented by Perez-Atayde et al in the bone 
marrow biopsiesof children with ALL.(50) Further studies in cases of multiple myelomas, 
Acute myeloid leukaemia (AML) and other myeloproliferative disorders (MPD) have also 
shown a similar feature.  
It is widely known that MDS is a preleukaemic condition with a propensity to transform into 
acute leukaemia. The objective to evaluate the MVD in MDS in this present study was 
considered based on previous studies done by several investigators who demonstrated an 
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enhanced degree of angiogenesis in the bone marrow of patients with various haematological 
malignancies such as multiple myeloma, ALL, AML and CLL(33).   
The enumeration of the microvessel density was performed using the antiCD34 
immunohistochemical marker which stains the endothelial cells. It is essential to recall that 
endothelial cells also show positive staining for an array of commonly employed markers 
such CD31, PECAM-1, VE-Cadherin, Factor VIII etc, which are also known to reliably 
delineate endothelial cells in tissue sections. Numerous studies done on many cancers have 
used one or more of these markers for reliably staining the endothelium.  
Until now, there is no specific advantage of using a particular marker for the endothelium.  
Since anti CD34 reliably stains the endothelium with less degree of background staining, this 
marker was selected for the study. Moreover, in the setting of bone marrow, CD34 is also 
expressed by blasts. Hence, the number and distribution of these blasts in relation to the 
endothelial cells can also be possibly noted.   
This advantage of using the same marker i.e anti-CD34 to pick up both the endothelial cells 
and the blasts is not without its own disadvantage. First, in the setting of acute leukaemia or 
in MDS RAEB-II, the presenceof a high proportion of blasts obscures the endothelial vessels 
and may create confusion in the number and morphology of the endothelial cells. Second, 
microvessels, when cut in cross sections simulate blasts. In most instances, one can reliably 
identify the blasts based upon the granular staining nature, while the endothelial cells show a 
strong uniform positivity. 
In this regard, it is worth mentioning that studies evaluating angiogenesis in breast cancers 
and other organs have claimed that VE Cadherin and PECAM are unique to endothelial cells 
and hence are more useful for evaluating angiogenesis. (51) 
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The present study demonstrated a significant difference in the bone marrow MVD between 
MDS cases compared to the non MDS control group (p-value:0.000). The mean MVD was 
higher in the bone marrows of patients with MDS. There was no significant correlation 
between the MVD and the age, sex or the blast percentage. 
Persons who had increased cellularity in the marrow manifested an increase in the mean 
MVD compared to those with normocellular and hypocellular marrows. The reason for this 
association is hypothesized as follows: There is an important interdependence between the 
bone marrow vessels and its vascular bed. Endothelial cells and blood cells develop together 
and influence each other even from the stages of embryogenesis.  The finding of an increased 
mean number of microvessels in patients with increased cellularity could possibly just 
represent a normal physiological response to cell proliferation in the setting of a 
hypercellular marrow.  
Studies using PET scan to demonstrate the blood flow in the human bone marrow show that 
vertebral bodies are the sites of maximum blood flow followed by posterior – superior pelvis 
and then the other regions of pelvis. The reason for this variation could possibly be due to the 
presence of  actively regenerating cellular marrow at these sites (flat bones)which have an 
increased physiological demand.(52) 
There is evidence that enhanced stimulation of erythropoiesis and granulopoiesis causes 
increase in blood flow to the marrow. The increased blood flow is characterised more often 
by vasodilationdue to release of nitric oxide (NO) or by the local accumulation of metabolic 
end products that have a vasodilatory effect, rather than a true increase in the number of 
blood vessels per unit area.(52) 
In a hypercellular marrow, when the cell turnover is high, an increased production of mature 
blood cells enter the sinusoids in turn dilating and expanding the sinusoidal network which is 
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observed as increased number of stainable vessels of varying sizes and an irregular dilated 
lumen containing blood cells. Thus at this stage, an increased degree of MVD in the cases of 
MDS with a hypercellular marrow could not be completely ascertained to be a part of the 
disease. 
In addition to the increase in the vessel density, several morphological patterns of vessels 
were observed in the marrow sections from both MDS and the normal controls. In normal 
marrow sections, most of the vessels observed were linear and more or less non branching or 
with occasional branching showing a barely recognizable lumen.  In marrow sections from 
MDS cases, there were non branching linear vessels, branching V or Y shaped vessels, 
minimally dilated  CD34 positive endothelium lined vessels and large irregularly dilated 
sinusoid like vessels. A point to note was that there was no increase in the normal number of 
arterioles in the MDS marrows when compared to the control group. 
Similar to what was observed in this study, Pruneri et al described three basic morphological 
types of blood vessels in the marrow of MDS patients: large, very irregular vessels with 
visible lumen, vessels with branched shape and sinusoid like vessels. He also was in 
agreement with Perez-Atayde et al who used the term “endothelial sprouts” for designating 
small vessels without discernible lumina.(34)(50) 
Standard pathological textbooks describe that angiogenesis in tissues can occur as result of 
outgrowth and sprouting from previously existent vessels or from endothelial progenitor cells 
of marrow origin. This process of angiogenesis involves vasodilation, increased vascular 
permeability, proteolytic disruption of the basement membrane and migration of the 
endothelial cells to the site of the new vessel formation. (30) 
It would be logical to consider that these different morphological patterns of blood vessels 
that were observed represent the different stages of angiogenesis.  In most of the marrows 
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that were assessed, more than one morphological pattern of blood vessel was noted. The 
morphology also might be reasonably influenced by the stromal cells such as adipocytes and 
fibroblasts and the degree of reticulin fibrosis. 
In several studies that have documented an increase in the MVD in solid tumours, the new 
vessels that were demonstrated were more or less alike capillaries with a thin, reasonably 
recognisable basement membrane or atleast a supporting stromal cell adjacent to the vessel. 
Large irregular dilated  sinusoid like vascular spaces were not separately identified.  Hence, 
an increase in the capillary like linear blood vessels can be attributed more or less to the sole 
purpose of an increased nutrient delivery to the metabolically active tumour cells while the 
irregular sinusoidal like vessels might represent a normally present sinus which has expanded 
due to increased haematopoiesis and serves for the exit of blood vessels. 
At this juncture, it becomes necessary to highlight another interesting concept proposed by 
Perez et al while explaining the reason for increased angiogenesis in bone marrow biopsies 
with Acute lymphoid leukaemia (ALL). They propose that in some cases, there may be a 
system of capillaries in the bone marrow that are not patent in the normal physiological 
milieu. These capillaries open up in times of increase demand of the hematopoietic tissue by 
an increased flow of blood, which is controlled by the local bone marrow environment. (50) 
Thus inthese cases, the increase in the MVD in the marrow simply might result due to more 
number of functional capillaries rather than formation of new vessels. 
In summary, an increase in the number of capillary sized microvessels, with branching and 
endothelial cells might represent a true neoangiogenesis stimulated by the abnormal bone 
marrow cells. An increased MVD if interpreted along with other stromal factors such as 
fibrosis might reasonably predict the behaviour of the hematopoietic tissue that are dependant 
on them. 
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The documentation of an increased degree of neovascularisation is not only an important part 
of histopathological examination, but can also serve to guide patient management and the 
choices of drugs used for treatment. In malignancies, where angiogenesis has been 
demonstrated to play a major role and to impact the prognosis, antiangiogenic drugs have 
been tried as an adjunct to the use of conventional chemotherapeutic drugs.  
The most important hematologic malignancy where an increased MVD was demonstrated  to 
affect the prognosis was multiple myeloma. Thalidomide which is a drug used in the 
treatment for multiple myeloma has antiangiogenic property.(53) 
Antiangiogenic drugs  target the endothelial cells and reduce the recruitment and proliferation 
of endothelial progenitor cells. The endothelial cells are generally considered to be 
genetically very stable compared to the malignant cells which as a rule are genetically very 
unstable. The malignant cells because of their increased genetic instability have a propensity 
to rapidly develop new mutations which confers them resistance to conventionally used 
chemotherapeutic drugs and a growth advantage in comparison with the normal cells.  
When the endothelial cells are targeted, it results in rapid reduction in the vessel density 
which inturn translates into decreased nutrition to the rapidly developing tumour cells. Hence, 
the tumour cells undergo apoptosis and degenerate due to absence of blood supply. 
Moreover, the endothelial cells donot acquire rapid mutations to anti angiogeneic drugs due 
to their genomically stable nature.  
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CONCLUSION: 
 
There are cellular alterations and stromal vascular changes observed in cases of 
myelodysplastic syndrome (MDS). The cellular changes, which have been documented by 
observation through light microscopy in the form of dysplasia of the blood cells is reflected 
in the CPD parameters of the peripheral blood cells in the automated haematology cell 
counter (Beckman Coulter DXH800). In addition to the differences in the  CPD values,  there 
are appreciable differences in the pattern of the scatter plots in persons with myelodysplastic 
syndrome compared to the non MDS controls. 
Out of all the CPD values that were analysed, the mean neutrophil volume (MNV), mean 
neutrophil scatter (MNS), mean monocyte volume (MMV) and the mean eosinophil scatter 
(MES)  values were found to be significantly different between MDS cases compared to the 
non MDS cases and the healthy donors. These values can prove to be useful in the 
identification of MDS when there is peripheral cytopenia(s). Although, at this point, it cannot 
be concluded that these four above mentioned parameters can be used as a screening or a 
diagnostic tool for MDS, their usefulness in doubtful cases of MDS with a normal karyotype 
is not clear and needs further work. 
Regarding the stromal vascular alterations, it can be concluded that there is an increase in the 
mean Micro Vessel Density (MVD) in the bone marrow environment of patients with MDS. 
The significance of the different morphological patterns that were observed needs further 
studies and correlation. It is known that the drugs used at present for the treatment of MDS, 
such as Lenalidomide also exert an antiangiogenic property. The relevance of an enhanced 
MVD in cases of MDS to that of development of acute leukaemia could not be exactly 
highlighted by this study. 
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LIMITATIONS OF THE STUDY: 
 
1.  The study did not have a proportionate number of cases in the various subtypes of MDS to 
assess the significance of the CPD parameters and the MVD among the subtypes. 
2. Though  a comparison among the various parameters were performed among the low and 
high grade cases, comparison based on the IPSS scoring would be more clinically relevant. 
3. Since the CPD values were obtained from the Beckman DxH 800 automated haematology 
cell counter, the applicability of these results to that obtained from other cell counters such as 
Sysmex etc.was not tested. 
4. The alterations in the CPD parameters and the MVD after the initiation of the treatment 
were not assessed. 
5. There were 6 cases of MDS in which the blood vessels in the trephine biopsy sections did 
not stain positively with anti CD34 immunohistochemistry. This could possibly be attributed 
to improper fixation and tissue processing. 
6. A comparison of the MVD of cases with MDS to other haematological conditions such as 
acute leukaemia, myeloproliferative disorders and aplastic anaemia was not performed due to 
financial constraints. 
 
 
 
 
 APPENDIX: 
PROFORMA FOR STUDY: 
NAME: 
AGE: 
SEX:  
PLACE: 
BIOPSY NO: 
HOSPITAL NO: 
CLINICAL HISTORY:  
Fatigue/ Tiredness/ Bleeding manifestations/ Infections/ Others 
(Others -  Repeated transfusions/ cigarette smoking) 
Family history of blood cancer: Yes / No 
LABORATORY TESTS: 
RBC Count: (Hb <10 gm/dl) 
ABSOLUTE NEUTROPHIL COUNT:(<1.8x10^9/L  or  > 13x10^9/L) 
PLATELET Count:                (<100x10^9/L  or >450x10^9/L)  
UNICYTOPENIA /  BICYTOPENIA / PANCYTOPENIA. 
 
BONE MARROW ASPIRATE AND TREPHINE BIOPSY: 
CELLULARITY:   Hypocellular/ Normocellular/ Hypercellular. 
STROMAL ALTERATIONS:   Altered topography. 
MICROVASCULAR DENSITY:    / hpf 
RETICULIN FIBROSIS:  Grade ……. 
DYSERYTHROPOIESIS: 
Ring sideroblasts. 
Nuclear budding / internuclear bridging/ karryorhexis/ multinuclearity/megaloblastoid 
changes. 
 
  
DYSGRANULOPOIESIS: 
Nuclear  hypolobation / Hypersegmentation of nuclei/ Cytoplasmic hypogranularity. 
 
DYSMEGAKARYOPOIESIS: 
Micromegakaryocytes/ Hypolobated nuclei/pawn ball appearance. 
 
CATEGORY: ……………………….. 
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